Debra L. Richardson, M.D.
Stephenson Cancer Center, University of Oklahoma Health Sciences Center
Debra L. Richardson is Professor of Obstetrics & Gynecology and the Section Chief of Gynecologic
Oncology at the Stephenson Cancer Center, University of Oklahoma Health Sciences Center. Dr.
Richardson is a clinician, surgeon, and also a clinical trialist. She spends 50% of her time leading phase I
clinical trials within the SCC early phase drug development unit. She is a past GOG Foundation Scholar,
and a member of the GOG Partners Investigator Council. She is very involved in NRG Oncology, and is a
member of the Ovarian and Developmental Therapeutics Committees and the Chair of the Early Phase
Trial Oversight Committee. She completed residency at the University of Connecticut, Gynecologic
Oncology fellowship at The Ohio State University, and was faculty at UT Southwestern for 8 years. She
was the national PI of GOG 186J and GOG 3048 Uplift. She is the national PI of GOG 3096, REJOICE, the
phase 2/3 trial of RDXd in platinum resistant ovarian cancer. She has been on the board of directors of
the National Ovarian Cancer Coalition since 2015 and the Vice President of the board since 2019. She is
also currently serving a 3 year term on the Society of Gynecologic Oncology Board of Directors. Dr.
Richardson enjoys doing medical missions- and has completed one to Nigeria and one to the
Philippines.

CURRICULUM VITAE

        Debra Lynn Richardson, M.D., F.A.C.O.G., F.A.C.S

PERSONAL INFORMATION

Date of Birth:                          February 23, 1975

Place of Birth:                         Willingboro, New Jersey

Citizenship:                             United States

Work Address:                        Stephenson Cancer Center

                                    Section of Gynecologic Oncology

                                    800 N.E. 10^th Street, Suite 5050

                                    Oklahoma City, OK 73104

                                    Office: 405-271-8001

                                    Fax: 405-271-1006

                                    Email: [email protected]

PRESENT ACADEMIC RANK

Professor                                 Section Chief (December 2019-present)

Section of Gynecologic Oncology

                                                Department of Obstetrics and Gynecology

                                                University of Oklahoma Health Sciences Center

                                                (2017-present)

CAREER GOALS

Academic gynecologic oncologist with focus on prospective clinical studies and drug

development.

EDUCATION

Undergraduate                        University of Richmond

                                                Richmond, Virginia                                                                                                                            (1993-1994)

University of Virginia

                                                Charlottesville, Virginia                                                                                                                      Biology, Minor Foreign Affairs

                                                B.A. (1994-1997)

Medical                                   New York Medical College

                                                Valhalla, New York                                                               

M.D. (1997-2001)

Graduate                                 Mayo Graduate School

                                                Rochester, Minnesota

                                                Certificate in Clinical and Translational Science (2005-2010)

POSTGRADUATE TRAINING

Internship and Residency       Obstetrics and Gynecology

                                                University of Connecticut School of Medicine

                                                Farmington, Connecticut                                           

(2001-2005)

                                                Galloway Fellowship

Memorial Sloan-Kettering Cancer Center

                                                New York, New York                                                                                                                         (March 2004)

Fellowship                               Women’s Health          

                                                Mayo School of Graduate Medical Education                                                                                   Rochester, Minnesota

(2005-2006, completed 1 of 2 years)

Gynecologic Oncology

The Ohio State University College of Medicine

Columbus, Ohio

(2006-2009)

ACADEMIC POSITIONS

Assistant Professor                 Division of Gynecologic Oncology

                                                Department of Obstetrics and Gynecology

                                                The University of Texas Southwestern Medical Center

                                                (2009-2017)

Associate Professor                 Section of Gynecologic Oncology

                                                Department of Obstetrics and Gynecology

                                                University of Oklahoma Health Sciences Center

                                                (2017-2024)

Professor                                 Section of Gynecologic Oncology

                                                Department of Obstetrics and Gynecology

                                                University of Oklahoma Health Sciences Center

                                                (2024- )                      

CLINIC/HOSPITAL/INSTITUTIONAL AFFILIATIONS

The University of Texas Southwestern Medical Center        Dallas, Texas 2009- 2017

University Hospital Zale Lipshy                                             Dallas, Texas 2009- 2017

Parkland Memorial Hospital                                                   Dallas, Texas 2009- 2017

University Hospital St. Paul                                                   Dallas, Texas 2009- 2014

William P. Clements Jr. University Hospital                         Dallas, Texas 2014- 2017

OU Medical Center                                                                Oklahoma City, Oklahoma 2017-Present

BOARD CERTIFICATION

2007    Obstetrics and Gynecology         American Board of Obstetrics and Gynecology

2012    Gynecologic Oncology               American Board of Obstetrics and Gynecology

MEDICAL LICENSURE

2005 - 2010                             State of Minnesota     

2009 – 2020                            State of Texas

2017- Present                          State of Oklahoma

HONORS/AWARDS           

2001                                        Alpha Omega Alpha Honor Medical Society, New York Medical

College

2001                                        The Sanford Sall, M.D., Award in Obstetrics and Gynecology, given to                                                      a member of the graduating class who has demonstrated the greatest art and                                               achievement in the art and science of Obstetrics and Gynecology, New

                                                York Medical College

2001                                        Janet M. Glasgow Memorial Achievement Citation, American

Medical Women’s Association

2006                                        Speaker of the Month April 2006, Mayo Outreach to Students and

Teachers, Mayo Clinic

2007                                        Selected to attend Clinical Pharmacology of Anticancer Agents

Workshop, hosted by Cancer Education Consortium, Leesburg, Virginia

2008                                        Scholarship to attend the Thirteenth Winter Meeting of the Society of Gynecologic Oncologists, Park City, Utah

2012                                        Outstanding Reviewer for 2011 academic year, American Journal of Obstetrics and Gynecology

2014                                        Best Doctors in Dallas, D Magazine

2014                                        Top 10% reviewer for 2014, Obstetrics and Gynecology

2015                                        Best Doctors in Dallas, D Magazine

2015                                        Award for Best Abstract in Gynecologic Oncology, Hechanova M, Lin KY, Richardson DL, Kho KA. Risk of Occult Uterine Sarcoma in Women Undergoing Hysterectomy for Benign Indications. Plenary Session Oral Presentation. AAGL 44th Global Congress on Minimally Invasive Gynecology.

2015                                        Top 10% reviewer for 2015, Obstetrics and Gynecology

2016                                        Best Doctors in Dallas, D Magazine

2016                                        Outstanding Reviewer, American Journal of Obstetrics and Gynecology

2017                                        Castle Connolly Top Doctor of Dallas          

2017                                        Best Doctors in Dallas, D Magazine

2019                                        2018 Top Reviewer, American Journal of Obstetrics and Gynecology

2020                                        Faculty Award for Teaching, Department of Obstetrics and Gynecology, University of Oklahoma Health Sciences Center

2021                                        Faculty Award for Teaching, Department of Obstetrics and Gynecology, University of Oklahoma Health Sciences Center

2022                                        SGO 2021 Best Clinical Practice Poster Award, Hardesty MM, Krivak T, Wright GS, Hamilton E, Fleming EL, Belotte J, Keeton E, Chen J, Clements A, Gray HJ, Konecny GE, Moore RG, Richardson D. Phase 2 OVARIO study of niraparib + bevacizumab therapy in advanced ovarian cancer following platinum-based chemotherapy with bevacizumab. Virtual Annual Meeting on Women’s Cancer

2022                                        Third Place Professional Poster, Katz M, Gandhi A, Valente A,  Richardson D, Holman L. Implementation of a Standard Same Day Discharge Protocol for Minimally Invasive Hysterectomies in the Division of Gynecologic Oncology: A Quality Improvement Project, Partners in Quality

2023                                        Faculty Award for Teaching, Department of Obstetrics and Gynecology, University of Oklahoma Health Sciences Center

2024                                        Top Doctors, 405 Magazine

2024                                        Faculty Award for Teaching, Department of Obstetrics and Gynecology, University of Oklahoma Health Sciences Center

2025                                        Top Doctors, 405 Magazine

GRANTS

7/1/2019-6/31/2024                 $136,275 2019 GOG Foundation Scholar Investigator Award

4/1/2023 – 3/31/2026              $596,401.00 Ovarian Cancer Research Program, Department of Defense. Targeting DCLK1-Driven Chemoresistance in Ovarian Cancer, Hannafon BN (Principal Investigator), Richardson DL co-investigator (1% effort)

1/1/2024 - 12/31/2026             $888,314.00 Ovarian Cancer Research Alliance, Foundation. Development of a novel DCLK1-targeted CAR-T to prevent ovarian cancer metastatic recurrence, Hannafon BN (Principal Investigator), Richardson DL co-investigator (2% effort)

CURRENT CLINICAL TRIALS

1. OU-SCC-STAR (IIT) NCT04068753      Richardson (Study PI)

GlaxoSmithKline: Phase II trial of niraparib in combination with TSR-042 (dostarlimab) in patients with recurrent or progressive cervical cancer. $457,369 paid to the institution.

2. BRE 344 EMBER NCT04188548            Richardson (Site PI)

Lilly: A phase 1a/1b study of LY3484356 administered as monotherapy and in combination with anticancer therapies for patients with ER+ locally advanced or metastatic breast cancer and other select non-breast cancers. $11,175 paid to institution. Closed to enrollment.

3. GYN84 NCT03393884               Richardson (Site PI)

Celsion

A Phase I/II study Evaluating the Dosing, Safety, Efficacy, and Biological Activity of Intraperitoneal GEN-1 (IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer) Administered in Combination with Neoadjuvant Chemotherapy (NACT) in Patients Newly Diagnosed with Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer. $94,736 paid to institution. Closed to enrollment.

4. RM 537/ GOG 3048 NCT03319628                    Richardson (Site PI, National PI GOG 308)

Mersana

A phase 1b, first-in-human, dose escalation and expansion study of XMT-1536 in patients with solid tumors likely to express NaPi2b. $986,965 paid to the institution. Closed to enrollment.

5. RM 662 NCT04180215                Richardson (Site PI)

Hookipa                                 

A Phase I/II study of HB-201 administration without and with nivolumab in human papillomavirus 16 positive (HPV 16+) confirmed cancers. $6,868 paid to the institution.

6. RM 706 NCT04247126                Richardson (Site PI)

Syros

A phase I study of SY-5609, an oral, selective CDK7 inhibitor, in adult patients with select advanced solid tumors. $167,256 paid to the institution. Closed to enrollment.

7. GOG 3035 NCT04498117           Richardson (Site PI)

A Multicenter Phase 3, Double-Blind, Placebo-Controlled Study Comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin- Oregovomab) vs Chemotherapy (Paclitaxel-Carboplatin- Placebo) in Patients with Advanced Epithelial Ovarian, Fallopian Tube or Peritoneal Carcinoma (FLORA-5). $45,656 paid to the institution. Closed to enrollment.

8. NRG                                              Richardson (Site-PI)

GY022 Assessment of Carboplatin Clearance Predictors: A PK Study on NCI-Sponsored Clinical Trials or Standard of Care Treatments Using Carboplatin. $1000 paid to the institution.

9. NRG                                             Richardson (Site-PI)

GY014 A Phase II Study of Tazemetostat (EPZ-6438) in Recurrent or Persistent Endometrioid or Clear Cell Carcinoma of the Ovary, and Recurrent or Persistent Endometrioid Endometrial Adenocarcinoma. Closed to enrollment. $50 paid to the institution.

10. NRG                                             Richardson (Site-PI)

GY020 A Phase III Randomized Trial of Radiation +/- MK-3475 (Pembrolizumab) for Newly Diagnosed Early Stage High Intermediate Risk Mismatch Repair Deficient (DMMR) Endometrioid Endometrial Cancer. Closed to enrollment. $85,300 paid to the institution.

11. ETCTN                                         Richardson (Site-PI)

9892 Phase I Dose-Escalation Bioavailability Study of Oral Triapine in Combination with Concurrent Chemoradiation for Locally Advanced Cervical Cancer (LACC) and Vaginal Cancer. $6624 paid to the institution. Closed to enrollment.

12. GOG 3049 NCT05329545           Richardson (International PI)

Mersana

Upifitimab rilsodotin maintenance in platinum-sensitive recurrent ovarian cancer (UP-NEXT). $30,550 paid to the institution. Closed to enrollment.

13. RM 811 NCT04644068                Richardson (Site PI)

AstraZeneca

A modular phase I/IIa, open-label,multicenter study to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of ascending doses of AZD5305 monotherapy and in combination with anti-cancer agents in patients with advanced solid malignancies. $3096 paid to the institution.

14. GYN114 NCT05483933              Richardson (Site PI)

Shattuck Labs

An open-label, phase 1b study of SL-172154 (SIRPα-Fc-CD40L) administered with either pegylated liposomal doxorubicin or mirvetuximab soravtansine in subjects with platinum-resistant ovarian cancers. Closed to enrollment.

15. GYN 116                                      Richardson (Site PI)

Immunogen/Abbvie

A Phase 1, First-in-Human, Open-Label, Dose-Escalation and Expansion Study of IMGN151 in Adult Patients with Recurrent Endometrial Cancer and Recurrent, High-Grade Serous Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers

16. RM 934 NCT05579366                Richardson (Site PI)

Profound Bio

Phase 1/2 study of PRO1184 in patients with locally advanced and/or metastatic solid tumors.

17. NRG-GY028                                Richardson (Site PI)

A Phase IB and Randomized Phase II Trial of Megestrol Acetate with or without Ipatasertib in Recurrent or Metastatic Endometrioid Endometrial Cancer.

18. QPT-ORE-004 NCT05335993     Richardson (Site PI)

CanariaBio

A clinical study evaluating a combination of oregovomab and niraparib in adult women with platinum sensitive recurrent ovarian cancer. Closed to enrollment.

19. AFT-50 EndoMAP NCT04486352 Richardson (Site PI)

Alliance Foundation

A phase IB/II multi-cohort study of targets agents with atezolizumab for patients with recurrent or persistent endometrial cancer.

20. PICCOLO NCT05041257            Richardson (Site PI)

ImmunoGen

Mirvetuximab soravtansine monotherapy in platinum-sensitive epithelial, peritoneal, and fallopian tube cancers. Closed to enrollment.

21. GOG 3082                                    Richardson (Site PI)

Acrivon

A Phase 1b/2 Basket Study of ACR-368 as Monotherapy and in Combination with Gemcitabine in Adult Subjects with Platinum-Resistant Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma Based on Acrivon OncoSignature® Status.

22. GOG 3083 NCT05611931           Richardson (Site PI)

Karyopharm

Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma (XPORT-EC-042).

23. RM 744 NCT0458750                              Richardson (Site PI)

PMV Pharmaceuticals

A Phase 1/2 Study of PC14586 in Patients with Advanced Solid Tumors Harboring a p53 Y220C Mutation (PYNNACLE)

24. RM 805 NCT                                            Richardson (Site PI)

Nurix Therapeutics

A Phase 1a, Dose Escalation, Safety and Tolerability Study of NX-1607, a Casitas B-lineage lymphoma proto-oncogene (CBL-B) inhibitor, in Adults with Advanced Malignancies, with Phase 1b Expansion in Select Tumor Types

25. RM 811                                                     Richardson (Site PI)

AstraZeneca

A Modular Phase I/IIa, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Ascending Doses of AZD5305 monotherapy and in combination with Anti-cancer Agents in Patients with Advanced Solid Malignancies

26. RM 853                                                     Richardson (Site PI)

Nimbus Therapeutics

A Phase 1/2, Open-label Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of NDI-101150 Administered as Monotherapy or in Combination with Pembrolizumab in Patients with Solid Tumors

27. RM 856                                                     Richardson (Site PI)

DualityBio

A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1303/BNT323 in Patients with Advanced/Metastatic Solid Tumors

28. RM 880                                         Richardson (Site PI)

Blueprint Medicines

A Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of BLU-222 as a Single Agent and in Combination Therapy for Patients with Advanced Solid Tumors. Closed to enrollment

29. RM 900                                         Richardson (Site PI)

Mersana

Phase 1, First-in-Human, Dose Escalation and Expansion, Multicenter Study of XMT-1660 in Participants with Solid Tumors

30. RM 922                                         Richardson (Site PI)

GlaxoSmithKline

A Phase 1 First Time-in-Human, Open-Label Study of GSK GSK4381562A Administered as Monotherapy and in Combination with Anticancer Agents in Participants with Selected Advanced Solid 922Tumors

31. RM 934                                         Richardson (Site PI)

ProfoundBio

Phase 1/2 Study of PRO1184 in Patients with Locally Advanced and/or Metastatic Solid Tumors

32. RM 999                                         Richardson (Site PI)

Scorpion Therapeutics

First-in-Human Study of STX-478, a Mutant-Selective PI3Kα Inhibitor as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumor

33. RM 1007                                       Richardson (Site PI)

34. RM 1032                                       Richardson (Site PI)

Allorian

A Phase 1/2, First-In-Human Study To Assess The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Mtd/Rp2d, And Anti-Tumor Activity Of Arts-021 As A Single Agent And In Combination Therapy In Patients With Advanced Solid Tumors

35. RM 1059                                       Richardson (Site PI)

A2A Pharmaceuticals

A Phase 1, open-label, dose-escalation and dose-expansion study evaluating AO-252, a protein-protein interaction inhibitor of TACC3, in advanced solid tumors including triple-negative breast cancer (TNBC), high-grade serous ovarian carcinoma (HGSOC), and endometrial cancer.

36. RM 1084                                       Richardson (Site PI)

OnCusp Therapeutics

A Phase 1, First-in-Human Study of CUSP06, a Cadherin-6 (CDH6)-directed Antibody-Drug Conjugate, in Patients with Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors

37. RM 1092                                       Richardson (Site PI)

Valerio Therapeutics

A phase 1/2 study of VIO-01 in Participants with recurrent solid tumors

38. RM 1104                                       Richardson (Site PI)

39. RM 1124 (Napistar)                      Richardson (Site PI)

40. UAB-2031                                    Richardson (Site PI)

Single-Arm Phase II Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients receiving Neoadjuvant Chemotherapy with Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer who are Folate Receptor positive

41. PRECISION-1                             Richardson (Site PI)

Aadi Bioscience

A Phase 2 Multi-center Open-label Basket Trial of Nab-sirolimus for Adult and Adolescent Patients With Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 or TSC2 Genes. Closed to enrollment.

PREVIOUS CLINICAL TRIALS

42. Lycera  NCT02929862                 Richardson (Site PI)

A phase 1/2A, multicenter, open-label study of LYC-55716 in adult subjects with locally advanced or metastatic cancer. Closed September 2019. $58,125 paid to institution.

43. RM 530 NCT03292172                Richardson (Site PI)

Genentech

Open-label, dose finding phase IB study to evaluate the safety, pharmacokinectics and clinical activity

of RO6870810 and atezolizumab (PD-L1 antibody) in patients with advanced ovarian cancer or triple negative breast cancer. Closed September 2019. $41,243 paid to institution.

44. RM 556 NCT03514121                Richardson (Site PI)

Five Prime

A phase Ia/Ib study of FPA150, an anti-B7-H4 antibody, in patients with advanced solid tumors. $7298 paid to institution. Closed prematurely by sponsor. Closed 9/24/20.

45. RM 558 NCT03421353                Richardson (Site PI)

AstraZeneca

A phase Ib/II, open-label, multicenter study to assess safety, tolerability, pharmacokinetics and preliminary anti-tumour activity of AZD9150 plus durvalumab alone or in combination with chemotherapy in patients with advanced, solid tumours and subsequently in patients with non-small-cell lung cancer. Closed to enrollment 10/11/19. $683,618 paid to institution.

46. RM 579 NCT03568539                Richardson (Site PI)

Innovent Biologics                 

An open-label, phase Ib multicenter study of IBI308 in subjects with advanced/metastatic malignancies. Closed 8/30/21. $142,978  paid to institution.

47. RM 587 NCT02476955                Richardson (Site PI)

ArQule, Inc                            

An open-label phase Ib study of ARQ092 in combination with carboplatin plus paclitaxel, in combination with paclitaxel, or in combination with anastrazole in subjects with select solid tumors . Closed November 2019. $10,635  paid to institution.

48. Merck        3475-775 NCT03517449        Richardson (Site PI)

A multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with pembrolizumab versus treatment of physician’s choice in participants with advanced endometrial cancer. Closed to enrollment. $75,047 paid to institution.

49. GYN 90 NCT02454010               Richardson (Site PI)

Fujifilm

A Phase 1 dose-escalation study of radio-labeled antibody, FF-21101(90Y) for the treatment of advanced cancer. $206,138 paid to the institution.

50. GYN 96 NCT04493619               Richardson (Site PI)

Plexxikon

A multicenter, open-label, parallel, phase 2a study of PLX2853 monotherapy in advanced gynecological malignancies with a known ARID1A mutation and phase Ib/2a study of PLX2853/carboplatin combination therapy in platinum-resistant epithelial ovarian cancer. $23,196 paid to the institution.

51. GYN 85 NCT03695380               Richardson (Site PI)

Roche

A phase Ib study of cobimetinib administered in combination with niraparib, with or without atezolizumab, to patients with advanced platinum-sensitive ovarian cancer. $22,471  paid to institution.

52. RM 606 NCT03834948                Richardson (Site PI)

Arch Oncology: A Phase 1/2 Multicenter, Open-Label, Dose-Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of AO-176. $9987 paid to the institution. Closed prematurely by study due to toxicity. Closed 12/16/22.

53. GYN 86 NCT03639246               Richardson (Site PI)

Aravive, Inc

A phase Ib/2 randomized, controlled study of AVB-S6-500 in combination with pegylated liposomal doxorubicin or paclitaxel in patients with platinum-resistant recurrent ovarian cancer. $74,630 paid to the institution. Closed to enrollment.

54. GYN 93 NCT04406623               Richardson (Site PI)

Shattuck Labs

Phase IA/IB dose escalation study of the agonist redirected checkpoint, SL-172154 (SIRPα-Fc-CD40L), given intravenously alone or in combination, in subjects with ovarian cancer, squamous cell carcinoma of the head and neck and cutaneous squamous cell carcinoma. $118,062 paid to the institution. Closed to enrollment.

55. RM 541 NCT03329001                Richardson (Site PI)

Tesaro

An open-label, randomized-sequence, multicenter, single-crossover study to assess the relative bioavailability and bioequivalence of niraparib tablet formulation compared to niraparib capsule formulation in patients with advanced solid tumors. Closed to enrollment. $152,831  paid to institution.

56. RM 569 NCT03134638                Richardson (Site PI)

Syros                                      

A phase 1 study of SY-1365, a selective CDK7 inhibitor, in adult patients with advanced solid tumors. Closed to enrollment. $321,916 paid to institution.

57. RM 630 NCT03872206                Richardson (Site PI)

Harpoon                                 

A phase 1/2a open-label, multicenter, dose escalation and dose expansion study of the safety, tolerability, and pharmacokinetics of HPN536 in patients with advanced cancer associated with mesothelin expression who have failed standard available therapy. Closed to enrollment. $410,567 paid to the institution.

58. RM656 NCT04042116                 Richardson (Site PI)

Clovis Oncology: A Phase 1b/2, Open-Label Study to Evaluate the Safety and Efficacy of Lucitanib in Combination with Nivolumab in Patients with Advanced, Metastatic Solid Tumor. Closed to enrollment. $215,427 paid to the institution.

59. Karyopharm NCT03555422                     Richardson (Site PI)

SIENDO: A Randomized, Double-Blind, Phase 3 Trial of Maintenance with Selinexor/Placebo After Combination Chemotherapy for Patients with Advanced or Recurrent Endometrial Cancer. Closed to enrollment. $91,165 paid to the institution.

60. Tesaro        NCT03326193                        Richardson (Site PI)

Ovario: A phase 2, single-arm, open label study of maintenance therapy with niraparib + bevacizumab in patients with advanced ovarian cancer after response on frontline platinum-based chemotherapy. Closed to enrollment. $138,584 paid to institution.

61. RM 584 NCT03601897                Richardson (Site PI)

Deciphera Pharmaceuticals: An open-label, multicenter, phase Ib/2 study of rebastinib in combination with paclitaxel to assess safety, tolerability, and pharmacokinetics in patients with advanced or metastatic solid tumors. Closed to enrollment. $348,932 paid to institution.

62. RM 833 (LM102-01-101)             Richardson (Site-PI)

LaNova:  A Phase I, First-in-Human, Open-Label, Dose Escalation Study of LM-102 injection in Subjects with CLDN18.2-Positive Advanced Solid Tumors. Closed 7/1/22, study terminated early by sponsor. $4320 paid to institution.

63. NRG                                             Richardson (Site-PI)

GY006: A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination with Intravenous Triapine in Women with Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer. Closed to enrollment 9/22/22. $306,000 paid to institution.

64. GOG 3028                                    Richardson (Site-PI)

Agenus: RaPiDS: A Phase 2 Study of Anti-PD-1 Independently or in Combination with Anti-CTLA4 in Second-Line Cervical Cancer. $112,988 paid to institution.

PROFESSIONAL ORGANIZATIONS

American Board of Obstetrics and Gynecology

Wrote questions for ABO+G Gynecologic Oncology written examination 2017, 2019, 2020, 2021

Oral Board Examiner-Gynecology November 2018, 2019, 2021-24

American College of Obstetricians and Gynecologists, Fellow 2009

American College of Surgeons, Fellow 2012

American Gynecological and Obstetrical Society, Fellow 2021

American Medical Association 1998

Alpha Omega Alpha Honor Society 2001

American Society of Clinical Oncology 2007, Full member

Richardson DL and Moore K. Is There a Role for Maintenance PARP for Patients with Platinum-Sensitive Ovarian Cancer? Yes: A Therapeutic Revolution. ASCO Connection April 2018

Chair, Gynecologic Cancer Oral Abstract Session, American Society of Clinical Oncology Annual Meeting 2022

  Gynecologic Oncology Group/NRG 2007

Principal Investigator: GOG186J:  A Randomized Phase IIB Evaluation of Weekly Paclitaxel (NSC #673089) PLUS Pazopanib (NSC #737754) versus Weekly Paclitaxel Plus Placebo in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma.

Principal Investigator GOG Foundation GOG 3048: A phase 1b, first-in-human, dose escalation and expansion study of XMT-1536 in patients with solid tumors likely to express NaPi2b

Society of Gynecologic Oncology 2006, Full member         

Abstract grader for Forty-first Annual Meeting Fall 2009

Course director Education Forum I: SGO White Paper Review, 2015 Annual Meeting on Women’s Cancer

Liaison to American College of Obstetricians and Gynecologists Committee on Gynecologic Practice 2015-2018

“Weapons of Choice” Panel Discussion, 2015 Annual Meeting on Women’s Cancer

Moderator Focused Plenary II: Old Drugs, New Tricks: Modifying Cancer Risk, 2016 Annual Meeting on Women’s Cancer

Moderator Developmental Therapeutics in Gynecologic Cancer, Webinar #8 Society of Gynecologic Oncology 2020 Annual Meeting on Women’s Cancer

Mock LOI Review Mentor, 2021 Virtual Annual Meeting on Women’s Cancer

Scientific Plenary VI: Tumor Board- SGO Feud: Midwest versus the Rest! Member of Midwest team

Board of Directors 2023-2026

Steering Committee, SGO 2025 Annual Meeting on Women’s Cancer

Moderator Scientific Plenary III: Brace for IMPACT: Late Breaking Abstracts, SGO 2025 Annual Meeting on Women’s Cancer

Southwestern Gynecologic Assembly

            Program Chair 2015- Fiftieth Annual Meeting December 2015

Texas Medical Association/ Dallas County Medical Society 2009-2017

Western Association of Gynecologic Oncologists 2016

            Moderator Session IV, 2016 Annual Meeting

            Moderator Featured Poster Presentation, 2021 Annual Meeting

            Vice President 2023-2024

COMMUNITY MEMBERSHIPS, SOCIETIES AND SERVICES

HysterSisters- Medical Advisory Team 2014-2017

Mayo Clinic Alumni Association 2006-present

Medical Mission Trip, Adamawa State, Nigeria, Christian Medical Fellowship (March 2007)

Medical Mission Trip, Kabankalan, Negros Occidental, Philippines, Aloha Medical Mission (March 2017)

Mentor, Senior High School Student, Independent Study and Mentorship Class, Liberty High School, Frisco, TX January-May 2017

National Ovarian Cancer Coalition

Medical Advisory Board 2011-present

Board of Directors 2015-present

Vice President, Board of Directors, 2019-present

New York Medical College Alumni Association 2001-present

University of Oklahoma Pre-Medical Women’s Society, panel member “Reproductive Health in Oklahoma” November 2017

University of Virginia Alumni Association 1997-present

COMMITTEES                               

2003-2005                               Gynecology Quality and Assurance Committee, Hartford Hospital

2003-2004                               Chair, Resident Recruitment Committee, University of Connecticut

                                                School of Medicine

2005-2006                               Mayo Outreach to Students and Teachers, Mayo Clinic

2005-2006                               Officer, Internal Medicine Women’s Office for Trainees, Mayo Clinic

2006                                        Clinical Research Training Program Evaluation Committee, Mayo

Clinic  

2007-2008                               Clinical Quality Management Policy Group, The Ohio State

University College of Medicine

2010- 2017                              Pharmacy and Therapeutics, Hematology Oncology Subcommittee, Parkland Hospital

2010- Present                          Developmental Therapeutics Committee, Gynecologic Oncology Group/ NRG Oncology

2011- 2017                              Data Safety Monitoring Committee, Simmons Cancer Center, University of Texas Southwestern Medical Center

2012-2012                               Interviewed University of Texas Southwestern Medical School applicants

2012-Present                           Ovarian Committee, Gynecologic Oncology Group/NRG Oncology

2012-2014                               Surgical Services Best Practice Committee, Parkland Hospital

2013-2017                               Specialty Representative for Obstetrics & Gynecology, North Texas Chapter of the American College of Surgeons

2013-2014                               Community Service Committee, Dallas County Medical Society

2013-2018                               Clinical Practice Committee, Society of Gynecologic Oncology

2014-2016                               Executive Committee, Southwestern Gynecologic Assembly

2015-2016                               Annual Meeting on Women’s Cancer (SGO) 2016 Program Committee

2015-2017                               Peri-operative Value Analysis Committee, Parkland Hospital

2015-2017                               Institutional Review Board 4, University of Texas Southwestern Medical

                                                Center

2016-2017                               Scientific Research Committee, Southwestern Gynecologic Assembly

2016                                        Western Association of Gynecologic Oncologists Annual Meeting 2016 Program Committee

2016                                        Nominations Committee, Society of Gynecologic Oncology

2017-Present                           Chair, NRG Oncology Early Phase Trial Oversight Committee

2018-2022                               Publications Committee, Society of Gynecologic Oncology

2018-Present                           Protocol Review Monitoring Committee, Stephenson Cancer Center

2018-Present                           Chair, Operations Committee, Stephenson Cancer Center

2018-2020                               Complications Reduction Team, OU Medical Center

2018-2020                               EHR Advisory Committee, OU Medical Center

2019-Present                           Clinical Research Disease Site Group: Gynecologic Cancer, Stephenson Cancer Center

2019-Present                           Clinical Research Disease Site Group: Early Phase and Ill-Defined Site, Stephenson Cancer Center

2019-2021                               Started Molecular Tumor Board, Stephenson Cancer Center

2019-2020                               Patient Blood Management Working Group, University of Oklahoma Health Sciences Center

2019-Present                           Chair, Safety Review Committee: A phase 1b, first-in-human, dose escalation and expansion study of XMT-1536 in patients with solid tumors likely to express NaPi2b

2019-2022                               American Society of Clinical Oncology Scientific Committee Gynecologic Cancer Track Member and Track Leader 2021-2022

2020-2022                               VTE Task Force, Oklahoma University Medicine

2020-Present                           Co-chair, COVID-19 Task Force, Stephenson Cancer Center

2020-2021                               Radiation Oncology Chair Search Committee, University of Oklahoma College of Medicine

2020-Present                           GOG Partners Investigator Council

2020-2021                               Western Association of Gynecologic Oncologists Annual Meeting 2021 Program Committee

2021-Present                           Clinical Competency Committee, Obstetrics and Gynecology Residency

2022-Present                           Pharmacy and Therapeutics Committee, OU Health

2022-Present                           Unified Communications Committee, OU Health

Professional Development

1. Attended ACS Surgeons as Leaders: From Operating Room to Boardroom Course June 24-27, 2018 Durham, North Carolina
2. Attended 2018 SGO Minimally Invasive Surgery Academy Workshop for Fellows as Mentor October 18-19, 2018 Atlanta, Georgia

EDITORIAL BOARD        

Associate Editor BioMed Central Cancer, Surgical Oncology, Cancer Imaging, and Interventional Therapeutics Section 2014-January 2020

Associate Editor Gynecologic Oncology Reports 2016-present

REVIEWERSHIP

American Journal of Obstetrics and Gynecology March 2010- present

Annals of Surgical Oncology 2010, 2014

BioMed Central Cancer 2015-present

Cancer 2020

Cancer Management and Research 2020

Gynecologic Oncology April 2007- present

Gynecologic Oncology Reports April 2016-present

Journal of the American College of Surgeons October 2015

Lancet Oncology 2020-present

Obstetrics and Gynecology June 2009- present

Cancer Research UK, Clinical Trials Awards & Advisory Committee, reviewed application C8361/A17611

“A prospective randomized Phase III trial of carboplatin/gemcitabine/bevacizumab vs carboplatin/pegylated liposomal doxorubicin/bevacizumab in patients with platinum-sensitive recurrent ovarian cancer.” September 2013

Cancer Research UK, Clinical Trials Awards & Advisory Committee, reviewed application C14202/A18781 “PETROC - A phase II/III study of intraperitoneal (IP) plus intravenous (IV) chemotherapy versus IV carboplatin plus paclitaxel in patients with epithelial ovarian cancer optimally debulked at surgery following neoadjuvant intravenous chemotherapy.” April 2014

NCI Cancer Clinical Investigator Team Leadership Awards (CCITLA) Application Review 2020

Investigator-Initiated Research – Expansion – 7 (IIR-E-7) peer review panel of the FY24 Ovarian Cancer Research Program (OCRP) for the Department of Defense (DOD) October 2024
 

ADVISORY BOARD

2015, 2019, 2021, 2023, 2024        AstraZeneca

2015-2020                   Genentech

2018                            Ipsen Bioscience

2019                            Foundation Medicine

2019                            Tesaro

2019                            Bayer

2020                            Deciphera

2020-                           Mersana

2020-                           GlaxoSmithKline

2022-                           Immunogen

2023-                           Eisai

2023                            Profound Bio

2024                            Daiichi Sankyo

2024                            Repare Therapeutics

2024                            Incyclix Bio

STEERING COMMITTEE

2018-Present               Ovario: A Phase 2, Single-Arm, Open-Label Study of Maintenance Therapy with Niraparib + Bevacizumab in Patients with Advanced Ovarian Cancer after Response on Frontline Platinum-Based Chemotherapy (Tesaro)

2018-Present               SIENDO: A Randomized, Double-Blind, Phase 3 Trial of Maintenance with Selinexor/Placebo after Combination Chemotherapy for Patients with Advanced or Recurrent Endometrial Cancer (Karyopharm Therapeutics)

2021-Present               Executive Steering Committee: UPLIFT A Phase 1b/2 First-in-Human, Dose Escalation and Expansion Study of XMT-1536 in Patients with Solid Tumors Likely to Express NaPi2b

2023-Present               ENGOT-EN20/GOG-3083/XPORT-EC-042 A phase 3, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients with P53 wild-type, advanced or recurrent endometrial carcinoma

LECTURES

05/2003                                   Herpes Simplex Virus and Pregnancy, Perinatal Conference

Hartford Hospital, Hartford, Connecticut

10/2004                                   Small Bowel Obstruction, Grand Rounds, Hartford Hospital,

                                                Hartford, Connecticut

10/2006                                   How to Stay Out of Hot Water: A Fellow’s Perspective,                  

                                    Grand Rounds, The Ohio State University School of Medicine,

                                    Columbus, Ohio

07/2007                                   The Consumer’s Guide to Statistics, Resident Didactics, The Ohio

State University School of Medicine, Columbus, Ohio

11/2007                                   Human Papillomavirus and Cervical Cancer, Medical Student

Didactics, The Ohio State University School of Medicine, Columbus, Ohio

05/2008                                   Human Papillomavirus and Cervical Cancer, Medical Student

Didactics, The Ohio State University School of Medicine, Columbus, Ohio

06/2008                                   Vulvar and Vaginal Malignancies, Resident Didactics, The Ohio State

                                                University School of Medicine, Columbus, Ohio

10/2008                                   Chemotherapy for Gynecologic Malignancies, Radiation Oncology Resident Didactics, The Ohio State University School of Medicine,

                                                Columbus, Ohio

11/2009                                   How to Stay Out of Hot Water: Avoiding and Managing Complications,

Resident didactics, University of Texas Southwestern Medical Center, Dallas, Texas

09/2010                                   How to Stay of Out of Hot Water:  Avoiding and Managing Complications, University Medical Center Brackenridge, Austin, Texas

11/2010                                   Vulvar and Vaginal Malignancies, Resident didactics, University of Texas Southwestern Medical Center, Dallas, Texas

03/2011                                   Introduction to Gynecologic Oncology, Medical Student Lecture, University of Texas Southwestern Medical Center, Dallas, Texas

06/2011                                   Thromboembolic Disease and Malignancy: Prevention and Treatment, Grand Rounds, University of Texas Southwestern Medical Center, Dallas, Texas

09/2011                                   Ovarian Cancer, Cancer Support Community, Dallas, Texas

11/2011                                   Gestational Trophoblastic Disease and Vaginal Cancer, Resident didactics, University of Texas Southwestern Medical Center, Dallas, Texas

11/2011                                   Ovarian Cancer, Cancer 101, Parkland Hospital, Dallas, Texas

02/2012                                   Ovarian Cancer, Cancer 101, Parkland Hospital, Dallas, Texas

03/2012                                   Advances in Gynecologic Oncology, Medicine Grand Rounds, Methodist Hospital, Dallas, Texas

06/2012                                   How to Stay Out of Hot Water: Avoiding and Managing Complications,

Grand Rounds, University of Texas Southwestern Medical Center, Dallas, Texas

06/2012                                   Clinical Trials 101, National Ovarian Cancer Coalition, Dallas, Texas

08/2012                                   Ovarian Cancer, Cancer 101, Parkland Hospital, Dallas, Texas

10/2012                                   Ovarian Cancer, Cancer 101, Parkland Hospital, Dallas, Texas

01/2013                                   Gynecologic Oncology CREOG Review, University of Texas Southwestern Medical Center, Dallas, Texas

04/2013                                   Ovarian Cancer, Cancer 101, Parkland Hospital, Dallas, Texas

09/2013                                   Ovarian Cancer, First Rock Fellowship Church, Aubrey, Texas

05/2014                                   Ovarian Cancer, Cancer 101, Parkland Hospital, Dallas, Texas

08/2014                                   Ovarian Cancer, Cancer 101, Parkland Hospital, Dallas, Texas

09/2014                                   Clinical Trials 101, Camp Mak-A-Dream, Gold Creek, Montana

10/2014                                   Early Stage Ovarian Cancer, Gynecologic Oncology Fellows Lecture, Dallas, Texas

12/2014                                   Introduction to Gynecologic Oncology, Medical Student Lecture, University of Texas Southwestern Medical Center, Dallas, Texas

12/2014                                   Epithelial Ovarian Cancer, Grand Rounds, University of Texas Southwestern Medical Center, Dallas, Texas

04/2015                                   Advanced Ovarian Cancer Clinical Trials, Gynecologic Oncology Fellows Lecture, Dallas, Texas

10/2015                                   Introduction to Gynecologic Oncology, Medical Student Lecture, University of Texas Southwestern Medical Center, Dallas, Texas

12/2015                                   What Would George Think? The Future of Cervical Cancer Screening, Fiftieth Annual Meeting Southwest Gynecologic Assembly, Dallas, Texas

12/2015                                   Early Stage Ovarian Cancer, Gynecologic Oncology Fellows Lecture, Dallas, Texas

05/2016                                   Advanced Ovarian Cancer Clinical Trials, Gynecologic Oncology Fellows Lecture, Dallas, Texas

06/2016                                   Cervical Cancer, Hematology Oncology Fellows Lecture, Dallas, Texas

06/2016                                   Introduction to Gynecologic Oncology, Medical Student Lecture, University of Texas Southwestern Medical Center, Dallas, Texas

08/2016                                   Ovarian Cancer, The Good, The Bad and The Ugly, Grand Rounds, University of Texas Southwestern Medical Center, Dallas, Texas

10/2016                                   Gynecologic Cancers, All Saints Lutheran Church Annual Cancer Luncheon, Arlington, Texas

10/2016                                   Introduction to Gynecologic Oncology, Medical Student Lecture, University of Texas Southwestern Medical Center, Dallas, Texas

10/2016                                   Early Stage Ovarian Cancer, Gynecologic Oncology Fellows Lecture, Dallas, Texas

05/2017                                   Introduction to Gynecologic Oncology, Medical Student Lecture, University of Texas Southwestern Medical Center, Dallas, Texas

05/2017                                   Early Stage Ovarian Cancer, Gynecologic Oncology Fellows Lecture, Dallas, Texas

07/2017                                   Cancer Overview, Medical Nutrition Therapy in Acute Care Class, School of Health Professions, Dallas, Texas

09/2017                                   A Randomized Phase IIB Evaluation of Weekly Paclitaxel plus Pazopanib versus Weekly Paclitaxel plus Placebo in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma, 2017 CTEP Early Drug Development Meeting. National Cancer Institute, Shady Grove, Maryland

11/2017                                   Genes and Cancer, Anatomy, Resident Lecture, Oklahoma City, Oklahoma

11/2017                                   Platinum-Sensitive Ovarian Cancer, Gynecologic Oncology Fellows Lecture, Oklahoma City, Oklahoma

01/2018                                   Genes and Cancer, Anatomy, Resident Lecture, Oklahoma City, Oklahoma

01/2018                                   Secondary Cytoreduction, Gynecologic Oncology Fellows Lecture, Oklahoma City, Oklahoma

02/2018                                   COCKTAIL Part 2: Targeted Treatment for Ovarian Cancer, Society of Gynecologic Oncology Webinar, SGO Connect Ed

03/2018                                   Genes and Cancer, Anatomy, Resident Lecture, Oklahoma City, Oklahoma

03/2018                                   Advanced and Metastatic Uterine Cancer, Fellow Lecture, Oklahoma City, Oklahoma

07/2018                                   Genes and Cancer, Anatomy, Resident Lecture, Oklahoma City, Oklahoma

08/2018                                   Anatomy Boot Camp: Surgical Tips and Tricks- How to Get Out of Trouble, Fellow Lecture, Oklahoma City, Oklahoma

09/2018                                   Introduction to Academic Medicine, Academic Medicine Interest Group Meeting, Oklahoma University College of Medicine

10/2018                                   Genes and Cancer, Anatomy, Resident Lecture, Oklahoma City, Oklahoma

10/2018                                   Stephenson Cancer Center Updates, Shultz Memorial Golf Classic, McKinney, Texas

11/2018                                   Ovarian Cancer: Part 1, Hematology and Oncology Fellow Lecture, Oklahoma City, Oklahoma

12/2018                                   Ovarian Cancer: Part 2, Hematology and Oncology Fellow Lecture, Oklahoma City, Oklahoma

01/2019                                   Genes and Cancer, Anatomy, Resident Lecture, Oklahoma City, Oklahoma

01/2019                                   Cervical Cancer Pathology/Molecular Characteristics, Fellow Lecture, Oklahoma City, Oklahoma

01/2019                                   Future of PARPi in the Up-Front Treatment of Ovarian Cancer, Society of Gynecologic Oncology 2019 Annual Winter Meeting, Squaw Valley, California

03/2019                                   Introduction to Clinical Trials, Foundation for Women’s Cancer Gynecologic Cancer Patient Education Course, Honolulu, Hawaii

03/2019                                   Precision Medicine, Education Forum V: Challenges and Opportunities of Delivering Prevision Cancer Care- Molecular Targeting, Society of Gynecologic Oncology 50^th Annual Meeting on Women’s Cancer, Honolulu, Hawaii

04/2019                                   Genes and Cancer, Anatomy, Resident Lecture, Oklahoma City, Oklahoma

05/2019                                   Secondary Cytoreduction, Fellow Lecture, Oklahoma City, Oklahoma

06/2019                                   Sometimes More is Better, and Sometimes More is Less, Poster Discussion: Gynecologic Cancer, 2019 American Society of Clinical Oncology Annual Meeting, Chicago, Illinois

07/2019                                   Genes and Cancer, Anatomy, Resident Lecture, Oklahoma City, Oklahoma

07/2019                                   PARP Inhibitors Outside of Frontline: Biomarkers of Response, OncLive 2019 State of the Science Summit: Ovarian Cancer, Oklahoma City, Oklahoma

08/2019                                   PARP Inhibitors Problem Based Learning, Fellow Didactics, Oklahoma City, Oklahoma

09/2019                                   Genes and Cancer, Anatomy, Resident Lecture, Oklahoma City, Oklahoma

09/2019                                   Cervical Cancer, 2019 Comprehensive Board Review in Hematology and Medical Oncology, UT MD Anderson Cancer Center, Houston, Texas

09/2019                                   Uterine Cancer, 2019 Comprehensive Board Review in Hematology and Medical Oncology, UT MD Anderson Cancer Center, Houston, Texas

09/2019                                   Ovarian Cancer, Lambda Delta Psi Sorority Ovarian Cancer Awareness Night, University of Oklahoma, Norman, Oklahoma

09/2019                                   CREOG Review- Oncology, 2 hour Resident Education, Oklahoma City, OK

10/2019                                   Ovarian Cancer (Genetics/Histopathology/Molecular Characterization), Fellow Didactics, Oklahoma City, Oklahoma

10/2019                                   Ovarian Cancer: Part 1, Hematology and Oncology Fellow Lecture, Oklahoma City, Oklahoma       

11/2019                                   Genes and Cancer, Anatomy, Resident Lecture, Oklahoma City, Oklahoma

11/2019                                   Ovarian Cancer: Part 2, Hematology and Oncology Fellow Lecture, Oklahoma City, Oklahoma

12/2019                                   Platinum Sensitive Ovarian Cancer, Fellow Didactics, Oklahoma City, Oklahoma

01/2020                                   Genes and Cancer, Anatomy, Resident Lecture, Oklahoma City, Oklahoma

01/2020                                   Vulvar and Vaginal Pathology, Reproduction Course, University of Oklahoma College of Medicine, Oklahoma City, Oklahoma

01/2020                                   Cervical and Uterine Pathology, Reproduction Course, University of Oklahoma College of Medicine, Oklahoma City, Oklahoma

01/2020                                   Ovarian Pathology, Reproduction Course, University of Oklahoma College of Medicine, Oklahoma City, Oklahoma

02/2020                                   Clinical Trials 101, Gynecologic Cancer Education Course, Let Every Woman Know, Anchorage, Alaska

02/2020                                   PARP Inhibitor Update: Who, When, Which, & Why, Gynecologic Cancer Education Course, Let Every Woman Know, Anchorage, Alaska

03/2020                                   Genes and Cancer, Anatomy, Resident Lecture, Oklahoma City, Oklahoma

05/2020                                   What, When, Where: Sequencing Therapies for Cervical Cancer, 11^th Annual International Symposium on Ovarian Cancer and Gynecologic Malignancies, Webinar due to COVID-19 (originally San Diego, California)

05/2020                                   Combination Antiangiogenic Strategies in Recurrent Gynecologic Malignancies. Distillation Developmental Therapeutics in Gynecologic Cancer, Webinar #8 Society of Gynecologic Oncology 2020 Annual Meeting on Women’s Cancer

05/2020                                   Genes and Cancer, Anatomy, Resident Lecture, Oklahoma City, Oklahoma

06/2020                                   Personalized Medicine, Targeted Therapies in Gynecologic Cancers, Fellow Lecture, Webinar, GYOEDU.org

07/2020                                   Genes and Cancer, Anatomy, Resident Lecture, Oklahoma City, Oklahoma

07/2020                                   Gynecologic Cancers 101, Lunch and Learn, Stephenson Cancer Center Clinical Trials Office, Oklahoma City, Oklahoma

09/2020                                   Genes and Cancer, Anatomy, Resident Lecture, Oklahoma City, Oklahoma

09/2020                                   Immunotherapy and PARP Inhibitors for Recurrent Ovarian Cancer, International Gynecologic Cancer Society Digital Annual Global Meeting Industry Symposium, ImmunoGen

09/2020                                   Ovarian Cancer, Lambda Delta Psi Sorority Ovarian Cancer Awareness Night, University of Oklahoma, Virtual

10/2020                                   Ovarian Cancer Genetics, Histopathology, Molecular Characterization, Fellow Didactics, Oklahoma City, Oklahoma

10/2020                                   Combining Targeted Agents and Immune Checkpoint Inhibitors in the Fight Against Advanced and/or Recurrent Endometrial Cancer, Saint Louis University, Virtual Grand Rounds

12/2020                                   Genes and Cancer, Anatomy, Resident Lecture, Oklahoma City, Oklahoma

01/2021                                   Genes and Cancer, Anatomy, Resident Lecture, Oklahoma City, Oklahoma

01/2021                                   Vulvar and Vaginal Pathology, Reproduction Course, University of Oklahoma College of Medicine, Oklahoma City, Oklahoma

01/2021                                   Cervical and Uterine Pathology, Reproduction Course, University of Oklahoma College of Medicine, Oklahoma City, Oklahoma

01/2021                                   Ovarian Pathology, Reproduction Course, University of Oklahoma College of Medicine, Oklahoma City, Oklahoma

03/2021                                   Genes and Cancer, Anatomy, Resident Lecture, Oklahoma City, Oklahoma

03/2021                                   NaPi2B as the Target, Antibody Drug Conjugates as a New Class of Agents in Treating Recurrent Ovarian Cancer, Industry Satellite Symposia Session at the SGO 2021 Virtual Annual Meeting on Women’s Cancer

04/2021                                   Surgical Management and Adjuvant Treatment Decision Making for Early Stage Cervical Cancer, Fellows’ Didactic Session, Oklahoma City, Oklahoma

04/2021                                   Cervical and Endometrial Cancers Lunch and Learn, Clinical Trials Office, Oklahoma City, Oklahoma

04/2021                                   Other Strategies for Treating Cervical Cancer, Great Debates and Updates in Women’s Oncology Virtual Meeting

05/2021                                   Genes and Cancer, Anatomy, Resident Lecture, Oklahoma City, Oklahoma

06/2021                                   A Tale of Three PARP Inhibitors, Poster Discussion, 2021 American Society of Clinical Oncology Annual Meeting

07/2021                                   Genes and Cancer, Anatomy, Resident Lecture, Oklahoma City, Oklahoma

08/2021                                   Genes and Cancer, Anatomy, Resident Lecture, Oklahoma City, Oklahoma

09/2021                                   Ovarian Cancer, Lambda Delta Psi Sorority Ovarian Cancer Awareness Night, University of Oklahoma, Virtual

10/2021                                   Other Strategies for Treating Cervical Cancer, Great Debates and Updates in

Women’s Oncology Virtual Meeting

11/2021                                   Genes and Cancer, Anatomy, Resident Lecture, Oklahoma City, Oklahoma

12/2021                                   CREOG Review- Oncology, 2 hour Resident Education, Oklahoma City, OK

01/2022                                   Genes and Cancer, Anatomy, Resident Lecture, Oklahoma City, Oklahoma

01/2022                                   GYN Dysplasia, Hyperplasia, and Malignancy, Reproduction Course, University of Oklahoma College of Medicine, Oklahoma City, Oklahoma

01/2022                                   Hereditary Cancer Syndromes, Reproduction Course, University of Oklahoma College of Medicine, Oklahoma City, Oklahoma

03/2022                                   Genes and Cancer, Anatomy, Resident Lecture, Oklahoma City, Oklahoma

04/2022                                   Cervical Cancer Pathology/Molecular Characteristics, Fellow Didactics Oklahoma City, Oklahoma

04/2022                                   Antibody Drug Conjugates in Ovarian Cancer: Have ADCs Finally Found Their Groove? Great Debates and Updates in Women’s Oncology Virtual Meeting

05/2022                                   Genes and Cancer, Anatomy, Resident Lecture, Oklahoma City, Oklahoma

06/2022                                   HemeOnc Fellows Conference, Cervical Cancer, Oklahoma City, Oklahoma

07/2022                                   Genes and Cancer, Anatomy, Resident Lecture, Oklahoma City, Oklahoma

07/2022                                   Uterine Clear Cell and Undifferentiated Cancers, Inaugural Endometrial Cancer Symposium: How Preventive and Precision-Based Approaches will Improve Patient Outcomes, Baltimore, Maryland

09/2022                                   Genes and Cancer, Anatomy, Resident Lecture, Oklahoma City, Oklahoma

09/2022                                   Antibody Drug Conjugates in Ovarian Cancer: Novel Interventions in Clinical Trials, Great Debates and Updates in Women’s Oncology Virtual Meeting

10/2022                                   Early Stage Ovarian Cancer, Fellow Didactics, Oklahoma City, Oklahoma

11/2022                                   Genes and Cancer, Anatomy, Resident Lecture, Oklahoma City, Oklahoma

11/2022                                   Frontline Maintenance Ovarian Cancer, Gyn Onc Fellow Didactics, Oklahoma City, Oklahoma

01/2023                                   Genes and Cancer, Anatomy, Resident Lecture, Oklahoma City, Oklahoma

01/2023                                   Hereditary Cancer Syndromes, Reproduction Course, University of Oklahoma College of Medicine, Oklahoma City, Oklahoma

01/2023                                   CREOG Review- Oncology, 2 hour Resident Education, Oklahoma City, OK

02/2023                                   ADCs: Hitting the Bullseye, SGO 2023 Winter Meeting, Whistler, British Columbia

03/2023                                   Upifitimab Rilsodotin, SGO Education Forum II session: New Drugs, New Problems, Tampa, Florida

03/2023                                   Novel combinations, biomarkers, and immune modulators to overcome recurrent ovarian cancer (PROC) Symposium at Society of Gynecologic Oncology, Tampa, Florida

05/2023                                   My Cancer has Returned, Now What? Platinum Resistant Ovarian cancer, NOCC Wellness Retreat, Las Colinas, Texas

06/2023                                   Advancements in Biomarker-Driven Care for Gynecologic Malignancies, WAGO Symposium, Monterey, California

10/2023                                   Genes and Cancer, Anatomy, Resident Lecture, Oklahoma City, Oklahoma

11/2023                                   Advanced Ovarian Cancer Therapies: PARP Inhibitors and Beyond, Great Debates and Updates in Women’s Oncology Virtual Meeting

11/2023                                   Management and Challenges of Cervical Cancer Treatment in the Second Line and Beyond, Great Debates and Updates in Women’s Oncology Virtual Meeting

11/2023                                   Endometrial Cancer Treatment Debate: Individualized Therapies Beyond Checkpoint Inhibitors, Great Debates and Updates in Women’s Oncology Virtual Meeting

01/2024                                   Genes and Cancer, Anatomy, Resident Lecture, Oklahoma City, Oklahoma

01/2024                                   Hot off the Press: Updates in Ovarian Cancer Clinical Trials, Society of Gynecologic Oncology 2024 Winter Meeting, Olympic Valley, California

02/2024                                   Hereditary Cancer Syndromes, Reproduction Course, University of Oklahoma College of Medicine, Oklahoma City, Oklahoma

03/2024                                   Genes and Cancer, Anatomy, Resident Lecture, Oklahoma City, Oklahoma

03/2024                                   GSK Med Symposium- The Evolution of Biomarkers in Gynecologic Malignancies, San Diego, California

04/2024                                   Genes and Cancer, Anatomy, Resident Lecture, Oklahoma City, Oklahoma

05/2024                                   Unveiling Novel Biomarkers and Charting Future Avenues in Ovarian Cancer, International Symposium on Ovarian Cancer and Other Gynecologic Malignancies Virtual Conference

05/2024                                   Ovarian Cancer and National Ovarian Cancer Coalition, Zentalis, Virtual Meeting

06/2024                                   Advanced Strategies in Ovarian Cancers: Exploring Emerging Therapies and Sequencing Strategies in Accordance with NCCN Guidelines, Western Association of Gynecologic Oncology, Seattle, Washington

07/2024                                   Establishing a Cellular Therapy Clinic- Academia. NRG Oncology Summer 2024 Symposium, Denver, Colorado

08/2024                                   Genes and Cancer, Anatomy, Resident Lecture, Oklahoma City, Oklahoma

09/2024                                   Genes and Cancer, Anatomy, Resident Lecture, Oklahoma City, Oklahoma

11/2024                                   Genes and Cancer, Anatomy, Resident Lecture, Oklahoma City, Oklahoma

ABSTRACTS

1. Bobrowski R, Noether J, Richardson D, Benn P.  What is the real risk for trisomy 18? Twenty-Fourth Annual Meeting of the Society for Maternal-Fetal Medicine, New Orleans, Louisiana, February 2-7, 2004.

2. Richardson DL, Chi D, Brown C, Barakat R.  The effect of surgical staging on epithelial stage I ovarian cancer.  Twenty-Fifth Annual Meeting of the New England Association of Gynecologic Oncologists, Bretton Woods, New Hampshire, June 10-12, 2005. 

3. Richardson DL, Mariani A, Cliby WA. #32 Risk factors for anastomotic leak after recto-sigmoid resection for ovarian cancer.  Thirty-Seventh Annual Meeting of the Society of Gynecologic Oncologists, Palm Springs California, March 22-26, 2006. Gynecol Oncol 101:S16, 2006.

4. O’Malley D, Kathari R, Huh W, Bryant S, Eaton L, Copeland L, Richardson D, Fowler J, Cohn D.  #29.  Platinum-based chemotherapy improves disease-free survival in clear cell carcinoma (CCC) of the Uterus.  Thirty-Eighth Annual Meeting of the Society of Gynecologic Oncologists, San Diego, California, March 2007.  Gynecol Oncol 104:S7, 2007.

5. Richardson DL, Kim K, Seamon LG, Cohn DE, O’Malley DM, Eaton L, Copeland LJ, Fowler JM.  #16037 Combination gemcitabine and cisplatin for recurrent ovarian cancer.  Forty-third Annual Meeting of the American Meeting of the American Society of Clinical Oncology, Chicago, Illinois, June 1-5, 2007.  J Clin Oncol 25:18S, 2007.

6. Seamon LG, Cohn DE, Richardson DL, Carlson MJ, Fowler JM. #16043 Platinum and taxane intraperitoneal chemotherapy after secondary cytoreductive surgery for recurrent ovarian carcinoma.  Forty-third Annual Meeting of the American Meeting of the American Society of Clinical Oncology, Chicago, Illinois, June 1-5, 2007.  J Clin Oncol 25:18S, 2007.

7. Seamon LG, Seward S, Richardson DL, Fowler JM, Cohn DE. Poster #11 Platinum and taxane intraperitoneal chemotherapy after secondary cytoreductive surgery for recurrent ovarian carcinoma. Thirty-Sixth Annual Meeting of the Western Association of Gynecologic Oncologists, Sunriver, Oregon, June 6-9, 2007.   

8. Richardson DL, Kim K, Seamon LG, Cohn DE, O’Malley DM, Eaton L, Copeland LJ, Fowler JM.  Combination gemcitabine and cisplatin for recurrent ovarian cancer.  Thirty-Sixth Annual Meeting of the Western Association of Gynecologic Oncologists, Sunriver, Oregon, June 6-9, 2007. 

9. Seamon LG, Cohn DE, Valmadre S, Richardson DL, Fowler, JF.  Robotic hysterectomy and lymphadenectomy for endometrial cancer:  technical aspect and details for success, The Ohio State University method.  Third International Congress of the Minimally Invasive Robotic Association, Rome, Italy, January 24-26, 2008.

10. Seamon LG, Cohn DE, Richardson DL, Carlson MJ, Fowler JM.  Robotic versus abdominal type III radical hysterectomy and lymphadenectomy:  The Ohio State University experience.  Third International Congress of the Minimally Invasive Robotic Association, Rome, Italy, January 24-26, 2008.

11. Richardson DL, Seamon LG, Carlson MJ, O’Malley DM, Fowler JM, Copeland LJ, Cohn DE.  #126 CA-125 decline in ovarian cancer patients treated with intravenous versus intraperitoneal platinum-based chemotherapy. Thirteenth Winter Meeting of the Society of Gynecologic Oncologists, Park City, Utah, February 15-17, 2008.

12. Richardson DL, Backes F, Seamon LG, O’Malley DM, Cohn DE, Fowler JM, Copeland LJ.  #25 Combination gemcitabine, platinum, and bevacizumab for the treatment of recurrent ovarian cancer.  Thirty-Ninth Annual Meeting of the Society of Gynecologic Oncologists, Tampa, Florida, March 9-12, 2008.  Gynecol Oncol 108; S13, 2008.

13. Richardson DL, Seamon LG, Carlson MJ, O’Malley DM, Fowler JM, Copeland LJ, Cohn DE.  #126 CA-125 decline in ovarian cancer patients treated with intravenous versus intraperitoneal platinum-based chemotherapy. Thirty-Ninth Annual Meeting of the Society of Gynecologic Oncologists, Tampa, Florida, March 9-12, 2008.  Gynecol Oncol 108; S57, 2008.

14. Richardson D, Dai Z, Papp A, Hampel H, de la Chapelle A, Sadee W.  Allele-specific loss of heterozygosity of APC in colorectal cancer.  Seventh Annual Ohio State University Medical Center Research Day, Columbus, Ohio, April 10, 2008. 

15. Seamon LG, Carlson MJ, Richardson DL, Cohn DE, Fowler JM, Copeland LJ, O’Malley DM.  #5583 Improved intraperitoneal chemotherapeutic toxicity profile for ovarian cancer: A modification of the taxane-platinum protocol in GOG-172.  Forty-Forth Annual Meeting of the American Society of Clinical Oncology, Chicago, Illinois, May 30-June 3, 2008.  J Clin Oncol 26:2008.

16. Fowler J, Seamon L, Richardson D, Valmadre S, Cohn D.  #2008 – 1712 The role of robotic surgery in gynecologic oncology.  Twelfth Biennial Meeting of the International Gynecologic Cancer Society, Bangkok, Thailand, October 25-28, 2008.    

17. Resnick KE, Alder H, Hagan JP, Richardson DL, Croce CM, Cohn DE.  #33 The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform.  American Society of Clinical Oncology- National Cancer Institute-European Organization for Research and Treatment of Cancer Annual Meeting on Molecular Markers in Cancer, Hollywood, FL, October 31-November 1, 2008. 

18. Myers TK, Elfrink SH, Elder JW, Kimball KJ, Hurt JD, Richardson DL, Ballard KS, Homesley HD, Cohn DE, Barnes MN, McMeekin DS.  #8 Low risk gestational trophoblastic disease: is more methotrexate better?  Fortieth Annual Meeting of the Society of Gynecologic Oncologists, San Antonio, Texas, February 5-8, 2009.  Gynecol Oncol 112; S5, 2009.

19. Seamon LG, Fowler JM, Richardson DL, Carlson MJ, Valmadre S, Phillips GS, Cohn De.  #12 A detailed analysis of the learning curve after 105 cases: robotic hysterectomy and pelvic-aortic lymphadenectomy for endometrial cancer. Fortieth Annual Meeting of the Society of Gynecologic Oncologists, San Antonio, Texas, February 5-8, 2009. Gynecol Oncol 118; S7, 2009.

20. Richardson DL, Backes FJ, Hurt JD, Seamon LG, Copeland LJ, Fowler JM, Cohn DE, O’Malley DM.  #41 Which factors predict bowel complications in patients with recurrent epithelial ovarian cancer being treated with bevacizumab?  Fortieth Annual Meeting of the Society of Gynecologic Oncologists, San Antonio, Texas, February 5-8, 2009.  Gynecol Oncol 112;S23, 2009.

21. Bakkum-Gomez JN, Richardson DL, Seamon LG, Aletti GD, Powless CA, Keeney GL, O’Malley DM, Cliby WA.  #42 Influence of intraoperative capsule rupture on outcomes in stage I epithelial ovarian cancer.  Fortieth Annual Meeting of the Society of Gynecologic Oncologists, San Antonio, Texas, February 5-8, 2009.  Gynecol Oncol 112; S23, 2009.

22. Bakkum-Gomez JN, Richardson DL, Seamon LG, Aletti GD, Powless CA, Keeney GL, O’Malley DM, Cliby WA.  #43 Is there a high-risk subgroup of stage I ovarian cancer most likely to benefit from 6 vs. 3 cycles of adjuvant chemotherapy?  Fortieth Annual Meeting of the Society of Gynecologic Oncologists, San Antonio, Texas, February 5-8, 2009.  Gynecol Oncol 112; S23, 2009.

23. Seamon LG, Richardson DL, Hurt, JD, Fowler JM, O’Malley DM, Copeland LJ, Cohn DE.  #112  Bevacizumab and weekly topotecan as salvage chemotherapy for ovarian cancer.  Fortieth Annual Meeting of the Society of Gynecologic Oncologists, San Antonio, Texas, February 5-8, 2009.  Gynecol Oncol 112; S57, 2009.

24. Richardson DL, Seamon LG, Hurt JD, Backes FJ, Copeland LJ, Fowler JM, Cohn DE, O’Malley DM.  #118 Is there a role for repeated treatment with bevacizumab in ovarian cancer patients?  Fortieth Annual Meeting of the Society of Gynecologic Oncologists, San Antonio, Texas, February 5-8, 2009.  Gynecol Oncol 112;S60, 2009.

25. Resnick K, Alder H, Alvarez-Secord A, Whitaker R, Heaphy C, Richardson D, Croce C, Cohn D. #227 miRNA patterns in ovarian cancer cell lines: correlation with serum studies. Fortieth Annual Meeting of the Society of Gynecologic Oncologists, San Antonio, Texas, February 5-8, 2009.  Gynecol Oncol 112; S115, 2009.

26. McBee WC, Richard SD, Seamon LG, Lesnock J, O’Malley DM, Richardson, DL, Krivak TC.  #283 Normalization of CA125 levels in ovarian cancer patients undergoing intraperitoneal chemotherapy.  Fortieth Annual Meeting of the Society of Gynecologic Oncologists, San Antonio, Texas, February 5-8, 2009.  Gynecol Oncol 112; S144, 2009.

27. Hurt JD, Richardson DL, Seamon LG, Fowler JM, Coopeland LJ, Cohn DE, Eisenhauer E, Salani R, O’Malley DM.  #305 Sustained PFS with weekly paclitaxel and bevacizumab in recurrent ovarian cancer.  Fortieth Annual Meeting of the Society of Gynecologic Oncologists, San Antonio, Texas, February 5-8, 2009.  Gynecol Oncol 112; S154, 2009.

28. Richardson DL, Backes FJ, Seamon LG, Hurt JD, Cohn DE, Fowler JM, Copeland LJ, O’Malley DM.  Does repeat usage of bevacizumab in patients with progressive recurrent ovarian cancer offer a survival advantage?  Eighth Annual Ohio State University Medical Center Research Day, Columbus, Ohio, April 2, 2009. 

29. Hurt JD, Richardson DL, Papp AC, Cohn DE, Fowler JM, Sadee W.  Loss of NF1 contributes to the progression of epithelial ovarian cancer.  Eighth Annual Ohio State University Medical Center Research Day, Columbus, Ohio, April 2, 2009. 

30. Hurt JD, Richardson DL, Papp AC, Cohn DE, Fowler JM, Sadee W.  Loss of NF1 contributes to the progression of epithelial ovarian cancer.  One Hundredth Annual Meeting of the American Association for Cancer Research, Denver, Colorado, April 18-22, 2009. 

31. Richardson DL, Backes FJ, Seamon LG, Hurt JD, Cohn DE, Fowler JM, Copeland LJ, O’Malley DM.  #e16510 Does repeat usage of bevacizumab in patients with progressive recurrent ovarian cancer offer a survival advantage?  Forty-Fifth Annual Meeting of the American Society of Clinical Oncology, Chicago, Illinois, May 29 – June 2, 2009. 

32. Wang R, Aletti G, Bakkum-Gamez J, Zivanovic O, Seamon L, Rheaume P, Richardson D, Eisenhauer E, Barakat R, Gostout B.  Residual disease and survival in stage III mucinous ovarian carcinoma: a multicenter collaboration.  Thirty-Eighth Annual Meeting of the Western Association of Gynecologic Oncologists Vancouver, British Columbia, June 24-27, 2009. 

33. Hurt JD, Backes FJ, Rheaume S, Richardson DL, Fowler JM, Copeland LJ, Cohn DE, Eisenhauer E, Eisenhauer E, O’Malley DM.  Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer.  Forty-first Annual Meeting of the Society of Gynecologic Oncologists San Francisco, California, March 14-17, 2010. Gynecol Oncol 116:3;S47, 2010.

34. Boren TP, Richardson DL, Kehoe SM, Miller DS.  The correlation of cone biopsy with findings at radical hysterectomy and the need for adjuvant radiation therapy.  The Forty-Sixth Annual meeting of the American Society of Clinical Oncology, Chicago, Illinois, June 4-8, 2010.  J Clin Oncol 28;15s, 2010.

35. Boren TP, Andrews SE, Nelson DB, Richardson DL, Kehoe S, Wingo, SN, Purinton SC, Miller DS.  Vesicovaginal Fistulas Following Pelvic Radiation for Gynecologic Malignancies:  Report of a Novel Surgical Technique.  Thirty-Ninth Annual Meeting of the Western Association of Gynecologic Oncologists, Santa Barbara, California, June 9-12, 2010.

36. Boren TP, Nelson DB, Richardson DL, Reisch J, Miller DS.  The incidence of Lymph Node metastasis Associated with Cervical Involvement in Endometrioid Endometrial Cancers.  Thirty-Ninth Annual Meeting of the Western Association of Gynecologic Oncologists, Santa Barbara, California, June 9-12, 2010.

37. Manders DB, Purinton SC, Lea J, Miller DS, Kehoe SM, Richardson DL.   Third line salvage chemotherapy for recurrent cervical cancer.  The Forty-Seventh Annual meeting of the American Society of Clinical Oncology, Chicago, Illinois, June 3-7, 2011.

38. Manders DB, Purinton SC, Lea J, Miller DS, Kehoe SM, Richardson DL.  Outcomes of third line chemotherapy for recurrent and persistent cervical cancer.  Fortieth Annual Meeting of the Western Association of Gynecologic Oncologists, Park City, Utah, June 16-18, 2011.

39. Manders DB, Purinton SC, Lea JS, Richardson DL, Miller DS, Kehoe SM.  Predictive value of carcinoembryonic antigen and cancer antigen 125 in identifying mucinous ovarian tumors.  Fortieth Annual Meeting of the Western Association of Gynecologic Oncologists, Park City, Utah, June 16-18, 2011. . Gynecol Oncol 123;442-63, 2011.

40. Nagel C, Denson W, Rogers P, Manders D, Richardson D, Kehoe S, Miller D, Lea J.  Survival impact of clinical trials in patients with recurrent cervical cancer.  Fortieth Annual Meeting of the Western Association of Gynecologic Oncologists, Park City, Utah, June 16-18, 2011.  Gynecol Oncol 123;447-8, 2011. Gynecol Oncol 123;445-6, 2011.

41. Nagel C, Denson W, Rogers P, Manders D, Richardson D, Kehoe S, Miller D, Lea J.  Challenging prognostic factors for chemotherapy resistance in high-risk gestational trophoblastic neoplasia.  Fortieth Annual Meeting of the Western Association of Gynecologic Oncologists, Park City, Utah, June 16-18, 2011.

42. Nagel C, Garcia-Soto A, Richardson D, Lea J, Miller D, Kehoe S.  Does myometrial invasion confer a poorer prognosis in uterine adenosarcoma?  Fortieth Annual Meeting of the Western Association of Gynecologic Oncologists, Park City, Utah, June 16-18, 2011. Gynecol Oncol 123;450,2011.

43. Rogers P, Paulsen A, Cethoute K, Richardson DL, Kehoe SM, Miller DS, Lea JS.  Factors associated with clinical trial screening failures in gynecologic oncology.  Fortieth Annual Meeting of the Western Association of Gynecologic Oncologists, Park City, Utah, June 16-18, 2011.

44. Davidson B, Nagel C, Richardson D, Kehoe S, Miller D, Lea J. #201 Challenging prognostic factors for chemotherapy resistance in gestational trophoblastic neoplasia. Forty-third Annual Meeting of the Society of Gynecologic Oncology, Austin, Texas, March 24-27, 2012. Gynecol Oncol 125;S84, 2012.

45. Backes F, Richardson D, McCann G, Salani R, Eisenhauer E, Fowler J, Copeland L, Cohn D, O’Malley D. #225 Should bevacizumab be continued after progression on bevacizumab in recurrent ovarian cancer? Forty-third Annual Meeting of the Society of Gynecologic Oncology, Austin, Texas, March 24-27, 2012. Gynecol Oncol 125;S94, 2012.

46. Elwell K, Nagel C, Lea J, Richardson D, Miller D, Kehoe S. #401 Effect of BMI on progesterone therapy for endometrial cancer.  Forty-third Annual Meeting of the Society of Gynecologic Oncology, Austin, Texas, March 24-27. Gynecol Oncol 125;S163, 2012.

47. Nagel CI, Moron A, Elwell KE, Kehoe SM, Lea J, Miller D, Richardson DL. Survival Outcomes after Recurrence in Endometrioid Compared to Papillary Serous/Clear Cell Carcinoma of the Uterus. Forty-first Annual Meeting of the Western Association of Gynecologic Oncologists, Huntington Beach, California, June 27-30, 2012.

48. Thomas S, Nagel I, Richardson DL, Kehoe SM, Miller DS, Lea J.  Incidence of Adnexal  Metastasis Requiring Surgical Intervention in Women with Advanced Cervical Cancer. Forty-first Annual Meeting of the Western Association of Gynecologic Oncologists, Huntington Beach, California, June 27-30, 2012.

49. Bevan C, Nagel CI, Boren T, Miller DS, Kehoe SM, Richardson DL, Albuquerque K, Lea J.  Stage IIIC1 versus IIIC2 Endometrial Adenocarcinoma of the Uterus: Analysis of Recurrence Patterns and Toxicity. Forty-first Annual Meeting of the Western Association of Gynecologic Oncologists, Huntington Beach, California, June 27-30, 2012.

50. Nagel CI , Street J, Kehoe SK, Richardson DL, Miller DS, Lea J. Clinical Course of Ovarian Cancer After Two Salvage Regimens. Forty-first Annual Meeting of the Western Association of Gynecologic Oncologists, Huntington Beach, California, June 27-30, 2012.

51. Bevan C, Nagel CI, Boren TP, Miller DS, Kehoe SM, Richardson DL, Lea J. Recurrence patterns in patients with stage IIIC1 versus IIIC2 endometrial adenocarcinoma. Proceedings of the 2012 ASCO Annual Meeting; 2012 June 1-5; Chicago, Illinois. J Clin Oncol 30, 2012. Suppl; e15501.  
52. Nagel C, Davidson B, Elwell K, Bevan C, Kehoe S, Richardson D, Lea J, Miller D. Assessment of the Accuracy of Preoperative and Intraoperative Endometrial Pathology in Uterine Carcinoma. Proceedings of Society of Gynecologic Oncologists 44^th Annual Meeting on Women’s Cancer. Los Angeles, California March 2013.

53. Nagel C, Davidson B, Elwell K, Bevan C, Kehoe S, Richardson D, Lea J, Miller D. Can Preoperative Factors Predict the Need for Postoperative Radiation in Patients with Endometrioid Adenocarcinoma of the Uterus? Proceedings of Society of Gynecologic Oncologists 44^th Annual Meeting on Women’s Cancer. Los Angeles, California March 2013.

54. Moron A, Manders D, Nagel C, Miller DS, Richardson D, Kehoe S, Albuquerque K, Lea J. Outcomes of locally advanced cervical cancer in an underserved indigent US population.  Forty-fourth Annual Meeting of the Society of Gynecologic Oncology, Los Angeles, California, March 8-12, 2013.
55. Lin K, Bryant S, Miller DS, Richardson D, Kehoe S, Lea J. Outcomes of Phenotypic Females with Dysgerminoma and 46, XY Karyotype. Forty-second Annual Meeting of the Western Association of Gynecologic Oncologists, Seattle, Washington, June 26-29, 2013.
56. Manders DB, Paulsen A, Richardson DL, Kehoe SM, Miller DS, Lea JS. Factors Associated with Clinical Trial Screening Failures in Gynecologic Oncology. Proceedings of Society of Gynecologic Oncologists 45^th Annual Meeting on Women’s Cancer. Tampa, Florida, March 22-25, 2014.
57. Manders DB, Miller DS, Richardson DL, Kehoe SM, Lea JS. Cervical Cancer – Distant Failure After Treatment of Para-Aortic Lymph Node Metastases. Forty-third Annual Meeting Western Association of Gynecologic Oncologists, Truckee, California, June 25-28, 2014.
58. Lin KY, Miller DS, Kehoe SM, Richardson DL, Lea JS. Isolated Ovarian Metastasis in Endometrial Adenocarcinoma of Uterus. Forty-third Annual Meeting Western Association of Gynecologic Oncologists, Truckee, California, June 25-28, 2014.

59. Manders DB, Nagel CI, Conrad LB, Lin KY, Richardson DL, Kehoe SM, Miller DS, Lea JS. Total Laparoscopic Radical Hysterectomy in the Obese Patient. American Brachytherapy Society 2014 GYN School, Chicago, Illinois, July 12-14, 2014. Brachytherapy 2015;14:94, 2014.
60. Conrad L, Miller D, Kehoe S, Richardson D, Lea J. Factors Influencing Primary Treatment in Advanced Vulvar Cancers. American Brachytherapy Society 2014 GYN School, Chicago, Illinois, July 12-14, 2014.
61. Richardson DL, Sill MW, Cho, JK, Pearl ML, Kehoe SM, Hanjani P, Zhou XC, Van Le L, Landrum LM, Gray HJ, Coleman RL. #  IGCSM-1335  A randomized placebo controlled phase IIb trial of weekly paclitaxel plus/minus pazopanib in persistent or recurrent ovarian cancer. Fifteenth biennial meeting of the International Gynecologic Cancer Society, Melbourne, Australia, November 8-11, 2014.
62. Tewari KS, Sill M, Monk BJ, Penson RT, Lankes H, Leitao MM, Ramondetta LM, Van Le L, Richardson DL, Landrum LM, DiSilvestro PA, Behbakht K, Ueland FR, Michael H, Birrer MJ. #24 Impact of circulating tumor cells (CTCs) on overall survival among patients treated with chemotherapy plus bevacizumab for advanced cervical cancer: an NRG Oncology/Gynecologic Oncology Group study. 2015 annual meeting on women’s cancer, Chicago, Illinois, March 28-31, 2015. Gynecol Oncol 137;S1:12, 2015.
63. Lawson, S, Folkert MR, Powers M, Wise E, Wolcott S, Richardson D, Carlson M, Kehoe S, Lea J, Albuquerque K. Operative Brachytherapy Catheter Placement and Subsequent Transport to an Outpatient Center for Treatment is Safe and Facilitates Effective Therapy for Gynecological Cancers. American Brachytherapy Society Annual Meeting. Orlando, Florida, April 9-11, 2015.
64. Lin K, Hechanova M, Richardson DL, Kho K.  Risk of occult uterine sarcoma in women undergoing hysterectomy for benign indications. 2015 ACOG Annual Clinical and Scientific Meeting, San Francisco, California, May 2-6, 2015.
65. Manders DB, Moron A, Albuquerque KV, Miller DS, Kehoe SM, Richardson DL, Lea JS. Locally Advanced Cervical Cancer: Effect of Radiation Dosage and Treatment Duration on Outcomes. Oral Presentation. Western Association of Gynecologic Oncologists Annual Meeting, Santa Rosa, CA, June 10-13, 2015.
66. Manders DB, Albuquerque KV, Richardson DL, Kehoe SM, Miller DS, Lea JS. Emphasis on Systemic Therapy for Women with Pelvic Bone Involvement at Time of Diagnosis of Cervical Cancer. Poster Presentation. Western Association of Gynecologic Oncologists Annual Meeting, Santa Rosa, CA, June 10-13, 2015.
67. Conrad LB, Miller DS, Kehoe SM, Richardson DL, Lea JS. Defining optimal management of midline vulvar cancers. Western Association of Gynecologic Oncologists Annual Meeting, Santa Rosa, CA, June 10-13, 2015.
68. Hechanova M, Lin K, Richardson DL, Kho K. Risk of occult uterine sarcoma in women undergoing hysterectomy for benign indications. Best Abstract in the Category of Gynecologic Oncology. AAGL Forty-fourth Global Congress on Minimally Invasive Gynecology, Las Vegas, Nevada, November 15-19, 2015.

69. Cohn DE, Sill M, Walker JL, O’Malley DM, Nagel, CI, Rutledge T, Bradley WH, Richardson DL, Moxley K, Aghajanian C. #10 GOG186H: A randomized phase II evaluation of weekly paclitaxel versus weekly paclitaxel with oncolytic reovirus (Reolysin) in the treatment of recurrent or persistent ovarian, fallopian tube, or primary peritoneal cancer. Annual Meeting on Women’s Cancer, San Diego, California, March 19-22, 2016.

70. Palavalli Parsons LH, Roane B, Manders DB, Richardson DL, Kehoe SM, Carlson M, Miller DS, Lea JS. #381 Anti-angiogenic treatment of cervical cancer: significant tumor regression with severe toxicity.  Annual Meeting on Women’s Cancer, San Diego, California, March 19-22, 2016.

71. Kehoe SM, Mann ML, Richardson DL, Lea JS, Miller DS, Mauer CB. #468 Patient reported clinical outcomes and personal perspectives after risk reducing surgery.  Annual Meeting on Women’s Cancer, San Diego, California, March 19-22, 2016. Gynecol Oncol. 141(1):194, 2016 June.

72. Crim A, Gillen J, Liu C, Roane B, Ding K, Richardson D, Moore K. Prognostic Importance of Progression Free Survival Interval in Patients with IVB Endometrial Cancer Treated with Platinum-Based Therapy. 2016 Western Association of Gynecologic Oncologists Annual Meeting, Sedona, Arizona, June 8-11, 2016. Gynecol Oncol. 143(1):210-211, 2016 October.

73. Liu CS, Roane B, Crim A, Moore K, Richardson D.  The Role of Surgery in the Management of Stage IVB Endometrial Cancer. Poster presented. 2016 Western Association of Gynecologic Oncologists Annual Meeting, Sedona, Arizona, June 8-11.  

74. Vandersluis A, Wade K, Ding K, Backes F, Cosgrove C, El Naggar A, Richardson D, Liu C, Roane B, Erickson B, Leath CA, Moore KN, Gunderson CC. A Multi-Institutional Analysis of Surgery and Chemotherapy for Stage IVB Uterine Carcinosarcoma. Society of Gynecologic Oncology 2017 Annual Winter Meeting, Breckenridge, Colorado, January 26-28.

75. Palavalli Parsons L, Pederson R, Richardson D, Kho K. Risk of Occult Endometrial Cancer during Hysterectomy for Benign Indications.  2017 ACOG Annual Clinical and Scientific Meeting, San Diego, California, May 6-9, 2017.  

76. Kramer A, Mehta K, Kehoe SM, Carlson MJ, Lea J, Miller DS, Richardson DL. Detection of Chronic Hepatitis B in Gynecologic Oncology Patients Undergoing Systemic Chemotherapy.  2017 Western Association of Gynecologic Oncologists Annual Meeting, Rancho Mirage, California, June 14-17.

77. Palavalli Parsons LH, Lin KY, Miller DS, Richardson D, Carlson M, Kehoe S, Lea JS. Family History of Cancer Shows Improved Survival in Uterine Papillary Serous Carcinoma. 2017 Western Association of Gynecologic Oncologists Annual Meeting, Rancho Mirage, California, June 14-17.

78. Conrad LB, Schmidt S, Bailey AA, Richardson DL, Kehoe SM, Carlson M, Miller DS, Lea JS. Advanced Ovarian Cancer Patients with Sarcopenia May Benefit from Neoadjuvant Chemotherapy. 2017 Western Association of Gynecologic Oncologists Annual Meeting, Rancho Mirage, California, June 14-17.

79. Hardesty M, Krivak T, Chen J, Wainszelbaum M, Gupta D, Richardson D. A Phase 2, Single-Arm, Open-Label Study to Evaluate the Safety and Efficacy of Niraparib Combined with Bevacizumab as Maintenance Treatment in Patients with Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Following Frontline Platinum-Based Chemotherapy with Bevacizumab (OVARIO). European Society for Medical Oncology 2018 Congress, Munich, Germany, October 19-23.

80. Greenwood A, Castellano T, Richardson D. Provider Perspective on Medical Marijuana in Oncology. Society of Gynecologic Oncology 2019 Annual Winter Meeting, Squaw Valley, California, January 17-19.

81. Gillen J, Grimes S, Essel KG, Duininck G, Zhao D, Thompson JS, Richardson DL. #9 Impact of Financial Assistance Programs on Time to Completion of Therapy in Women Receiving Chemoradiation for Cervical Cancer. Society of Gynecologic Oncology Fiftieth Annual Meeting on Women’s Cancer, Honolulu, Hawaii, March 16-19, 2019

82. Son J, Carr C, Moulton L, Michener C, Men Y, Yen TT, Beavis A, Stone R, Wethington S, Burkett WC, Richardson DL, Stalet AS, Ahn S, Gehrig P, Torres D, Dowdy SC, Sullivan MW, Modesitt S, Watson C, Secord A, Veade A, Havrilesky L, Loreen A, Griffin K, Jackson A, Fader AN, Ricci S. Adjuvant treatment in high intermediate risk early stage endometrial cancer. Western Association of Gynecologic Oncology Annual Meeting, Huntington Beach, California, June 12-15, 2019

83. O’Malley DM, Richardson DL, Vergote I, Gilbert L, Martin LP, Mantia-Smaldone GM, Castro CM, Provencher D, Matulonis UA, Malek K, Moore KN. Mirvetuximab Soravtansine, a Folate Receptor alpha (FRα)-targeting Antibody-drug conjugate (ADC), in Combination with Carboplatin and Bevacizumab: Initial Results from a Phase 1b Study in Patients with Ovarian Cancer. European Society for Medical Oncology Congress 2019, Barcelona, Spain, September 27-October 1, 2019

84. Janku F, Birrer M, Richardson D, Chu C, Goel S, Tan G, Matin B, Kuida K, Ruiz-Soto R, Hamilton EP. Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination with Paclitaxel: Preliminary Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics in Patients with Advanced or Metastatic Solid Tumors. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Boston, Massachusetts, October 26-30, 2019

85. O’Malley DM, Hays J, Drescher C, Sachdev J, Nieves-Neira W, Wilky B, Huang M, Moore KN, Ortuzan W, Wijatyk A, Youssofian H, Kaleta R, Sapir I, Dupont C, Shapiro I, Richardson D. Single-agent Activity of a Novel PD-1 Inhibitor, AGEN2034, in Recurrent Ovarian Cancer. Subset Analysis of Phase 1 Dose-escalation NCT03104699 Study. Society for Immunotherapy of Cancer Thirty-fourth Annual Meeting, National Harbor, Maryland, November 7-10, 2019

86. Greenwood A, Castellano T, Jordan B, Richardson D. Perspectives on medical marijuana: A look at Society of Gynecology Oncology providers. Society of Gynecologic Oncology 2020 Annual Winter Meeting. Snowmass, Colorado, February 6-8, 2020

87. Gunderson CC, Walker JL, Mannel RS, Holman LL, Richardson D, Ding K, Moxley K, Landrum LM, Rowland M, Moore KN. A phase Ib trial of paclitaxel and carboplatin + galunisertib in patients with uterine and ovarian carcinosarcoma. Society of Gynecologic Oncology 2020 Annual Meeting on Women’s Cancer Virtual Meeting, April 2020

88. Hardesty MM, Krivak T, Wright GS, Hamilton E, Fleming EL, Gupta D, Keeton E, Chen J, Clements A, Gray HJ, Konecny GE, Moore RG, Richardson D. Phase 2 ovario study of niraparib + bevacizumab therapy in advanced ovarian cancer following front-line platinum-based chemotherapy with bevacizumab. Society of Gynecologic Oncology 2020 Annual Meeting on Women’s Cancer Virtual Meeting, April 2020

89. Richardson DL, Hamilton E, Tolcher A, Burns TF, Edenfield, WJ, Papadopoulos K, Matulonis UA, Huebner D, Mosher R, Jarlenski D, Pennock G, Cyr M, Ulahannan S, Moore KN.  A phase I study of XMT-1536 in patients with solid tumors likely to express NaPi2b: A summary of dose escalation. Society of Gynecologic Oncology 2020 Annual Meeting on Women’s Cancer Virtual Meeting, April 28, 2020

90. Richardson DL, Barve MA, Strauss JF, Ulahannan SV, Moore KN, Hamilton EP, Johnson ML, Papadopoulos KP, Zarwan C, Anderson CK, BuscemamJ, Doroshow DB, Edenfield WJ, Matulonis UA, Burns TF, Huebner D, Jansen VM, Mosher R, Jarlenski D, Tolcher AW. Phase I expansion study of XMT-1536, a novel NaPi2b-targeting antibody-drug conjugate (ADC): Preliminary efficacy, safety, and biomarker results in patients with previously treated metastatic ovarian cancer (OC) or non-small cell lung cancer (NSCLC). American Society of Clinical Oncology Annual Meeting, virtual meeting May 29-June 2, 2020 Abstract 3549

91. Janku F, Hamilton EP, Chu C, Richardson DL, Arend RC, Kuida K, Achour H, Ruiz-Soto R, Hays JL. An open-label, multicenter, phase Ib/II study of rebastinib in combination with paclitaxel in a dose-expansion cohort to assess safety and preliminary efficacy in patients with advanced or metastatic endometrial cancer. American Society of Clinical Oncology Annual Meeting, virtual meeting May 29-June 2, 2020 Abstract

92. Papadopoulos KP, Sharma M, Hamilton EP, Richardson DL, Hodgson G, Zhou L, Volkert A, Jolin HA, Madigan C, Kelly M, Roth DA. First-in-human phase I study of sy-5609, an oral, potent, and selective noncovalent CDK7 inhibitor, in adult patients with select advanced solid tumors. American Society of Clinical Oncology Annual Meeting, virtual meeting May 29-June 2, 2020 Abstract TPS366

93. Bendell J, Wang J, Bashir B, Richardson D, Bennett G, Campbell CT, Hennessy M, Jeffrey P, Kirui J, Mahnke L, Shapiro G. BT5528-100 phase I/II study; safety, pharmacokinetics and preliminary clinical activity of BT5528 in patients with advanced malignancies associated with EphA2 expression. American Society of Clinical Oncology Annual Meeting, virtual meeting May 29-June 2, 2020 Abstract TPS3655

94. Zhou X, Richardson D, Dowlati A, Goel S, Sahebjam S, Strauss J, Chawla S, Wang D, Samnotra V, Faller DV, Venatakakrisnan K, Gupta N. A randomized, crossover study to evaluate the effects of pevonedistat on the QTC interval in patients with advanced malignancies. Virtual 25^th Congress of the European Hematology Association, June 11-14, 2020, Poster EP835

95. Hamilton EP, Goel S, Arend R, Chu C, Richardson D, Diamond JR, John V, Janku F, Mathews C, JeBailey L, Kuida K, Achour H, Ruiz-Soto R, Hays J. A phase Ib/2 study of rebastinib and paclitaxel in advanced or metastatic platinum-resistant ovarian cancer.  European Society for Medical Oncology Virtual Congress 2020, September 19-21, 2020.

96. O’Malley DM, Richardson DL, Vergote I, Gilbert L, Martin LP, Mantia-Smaldone GM, Castro C, Provencher D, Matulonis UA, Zweidler-McKay P, Moore KN. Mirvetuximab sorvantansine (MIRV), a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin (CARBO) and bevacizumab (BEV): final results from a study in patients with recurrent platinum sensitive ovarian cancer. European Society for Medical Oncology Virtual Congress 2020, September 19-21, 2020, #3592.

97. Mahalingam D, Subbiah V, Owonikoko T, Ulahannan S, Richardson D, Kalyan A, Mulcahy M, Wheeler C, Matsushima S, Suzuki T, Subach RA, Johansen M, Madden T, Cheung K, Wages D. Phase I expansion study of P-cadherin-targeted antibody in advanced chemorefractory colorectal and pancreatic-biliary cancers. 2021 ASCO Gastrointestinal Cancers Symposium Virtual Meeting, January 15-17, 2020.

98. Gandhi A, Scott B, Hall S, Vesely S, Richardson D. Occurrence and timing of advanced care discussion in recurrent ovarian cancer patients participating in clinical trials remain to be optimized. 2021 Virtual Annual Cancer Research Symposium, Stephenson Cancer Center, February 5, 2021.

99. Hardesty MM, Krivak T, Wright GS, Hamilton E, Fleming EL, Belotte J, Keeton E, Chen J, Clements A, Gray HJ, Konecny GE, Moore RG, Richardson D. Phase 2 OVARIO study of niraparib + bevacizumab therapy in advanced ovarian cancer following platinum-based chemotherapy with bevacizumab. Virtual Annual Meeting on Women’s Cancer, March 19-25, 2021.

100. Gandhi A, Scott B, Hall S, Vesely S, Richardson D. Occurrence and timing of advanced care discussion in recurrent ovarian cancer patients participating in clinical trials remain to be optimized. Virtual Annual Meeting on Women’s Cancer, March 19-25, 2021.

101. Lheureux S, Spanngaard I, Hamilton E, Au-Yeung G, Richardson D, deMario M, Labriola-Thompkins E, Brennan B, Nueesch E, Chesne E, Franjkovic I, Lechner K, Kornacher M, Shapiro G. BET inhibitor RO6870810 and atezolizumab in patients with advanced ovarian cancer or triple negative breast cancer. AACR Annual Virtual Meeting April 4-14, 2021.

102. Richardson DL, Hamilton EP, Oaknin A, Randall LM, Banarjee SN, Taylor SK, Mileshkin LR, Coleman RL, Monk BJ, Mirza MR, Bernardo P, Mosher R, Jansen VM, Savarese A, Gorp TV, Madry R, Ray-Coquard IL, Concin N. Uplift (ENGOT-ov67): A pivotal cohort to evaluate XMT-1536 (upifitamab rilsodotin), a NaPi2b-directed antibody drug conjugate for platinum-resistant ovarian cancer. 2021 American Society of Clinical Oncology Annual Meeting June 4-8, 2021.

103. Ho AL, Posner MR, Niu J, Fu S, Leidner RS, Pearson AT, Chung KY, Richardson DL, Wang D, Pimentel A, Nieva JJ, Rosenberg A, Burman B, Iacobucci C, Qing X, Hwang A, Katchar K, Schlienger K, Matushansky I, Pfister DG. First report of the safety/tolerability and preliminary antitumor activity of HB-201 and HB-202, an arenavirus-based cancer immunotherapy, in patients with HPV16+ cancers. 2021 American Society of Clinical Oncology Annual Meeting June 4-8, 2021.

104. Janku F, Hamilton EP, Mathews CA, Chu C, Diamond JR, Hays JL, Arend RC, Cristofanilli M, Jewell A, Reichmann W, Kuida K, Achour H, Ruiz-Soto R, Richardson DL. Open-label, multicenter, phase 1b/2 study of rebastinib in combination with paclitaxel to assess safety and efficacy in patients with advanced or metastatic endometrial cancer. 2021 American Society of Clinical Oncology Annual Meeting June 4-8, 2021.

105. Clements A, Hardesty MM, Krivak T, Wright GS, Hamilton E, Fleming EL, Belotte J, Keeton E, Chen J, Gray HJ, Konecny GE, Moore RG, Richardson D. Phase 2 OVARIO Study of Niraparib + Bevacizumab Therapy in Advanced Ovarian Cancer Following Front-Line Platinum-Based Chemotherapy With Bevacizumab. Heartland Associated of Gynecologic Oncology, Madison, Wisconsin September 17-18, 2021.

106. Posner MR, Ho, AL, Niu J, Nabell L, Leidner RS, Nieva J, Richardson DL, Pearson AT, Wang D, Chung K, Adkins DR, Pimentel A, Wong S, Iacobucci C, Qing X, Katchar K, Schlienger K, Matushansky I, Fu S, Pfister DG. Safety, efficacy, and immunogenicity of arenavirus-based vectors HB-201 and HB-202 in patients with HPV16+ cancers. European Society for Medical Oncology Virtual Congress, September 16-21, 2021.

107. McKean M, Aljumaily R, A first in class phase I/II Study of the Novel Bicyclic Peptide and MMAE Conjugate, BT5528, in patients with Advanced Malignancies Associated with EphA2 Expression. AACR-NCI-EORTC Virtual Meeting October 7-10, 2021.

108. Concin N, Hamilton EP, Randall LM, Banerjee SN, Mileshkin LR, Coleman RC, Monk BJ, Mansoor MR, Savarese A, Ray-Coquard IL, Perez Fidalgo JA, Bernardo P, Putiri E, Burger RA, Mosher R, Richardson DL. UPLIFT (ENGOT-ov67/GOG-3048) A Pivotal Cohort of Upifitamab Rilsodotin, a NaPi2b-directed Antibody Drug Conjugate in Platinum-Resistant Ovarian Cancer. European Society of Gynaeological Oncology 2021 Congress, Prague, Czech Republic October 23-25, 2021.

109. Lakhani NJ, Richardson R, Kristedja T, Rangwala F, MD, McKay H, Gonzalez L, Ma B, Pandite L, Hamilton E. Phase 1 dose escalation study of the agonist redirected checkpoint, SL-172154 (SIRPα-Fc-CD40L) in subjects with platinum-resistant ovarian cancer. Society for Immunotherapy of Cancer 36^th Annual Meeting, Washington D.C, November 12-14, 2021.

110. Rippetoe J,  Xu C, Richardson D, Moore K, Hile E. Intra-Session Reliability in 1st-Ray Force Contribution to Push-off During Neurotoxic Chemotherapy. Stephenson Cancer Center Symposium, Oklahoma City, Oklahoma, March 4, 2022.

111. Katz M, Gandhi A, Valente A,  Richardson D, Holman L. Implementation of a Standard Same Day Discharge Protocol for Minimally Invasive Hysterectomies in the Division of Gynecologic Oncology: A Quality Improvement Project, Partners in Quality, Oklahoma City, Oklahoma, March 11, 2022.

112. Vergote I, Pérez Fidalgo A, Hamilton E, Valabrega G, Van Gorp T, Sehouli J, Cibula D, Levy T, Welch S, Richardson DL, Guerra Alía EM, Scambia G, Henry S, Pauline Wimberger P, Miller DS, Martínez J, Monk BJ, Shacham S, Mirza MR, Makker V. Prospective double-blind, randomized phase III ENGOT-EN5/GOG-3055/SIENDO study of oral selinexor/placebo as maintenance therapy after first-line chemotherapy for advanced or recurrent endometrial cancer. European Society for Medical Oncology March 2022, Virtual.

113. Richardson DL, Marth C, Banerjee S, Corr, B, Hays, J, Arend R, Tseng J, Cibula D,; Perez Fidalgo JA, Savarese A, Mądry R, Pothuri B, Coleman RL, Monk, BJ, Mirza MR, Ray-Coquard IL, Bernardo P, Putiri E, Shahverdyan A, Burger RA, Concin, N. UPLIFT (ENGOT-ov67/GOG-3048) A Pivotal Cohort of Upifitamab Rilsodotin (XMT-1536; UpRi), a NaPi2b-directed Dolaflexin Antibody Drug Conjugate (ADC) in Platinum-Resistant Ovarian Cancer. Society of Gynecologic Oncology 2022 Annual Meeting on Women’s Cancer, Phoenix, Arizona, March 18-21, 2022.

114. Richardson DL, Hamilton EP, Barve M,  Anderson CK, Taylor SK, Lakhani N, Buscema J, Tolcher AW, Zarwan C, Werner T, Hays J, Richards P, Arend R, Corr BR, Edenfield J, Putiri E, Bernardo P, Burger RA, Matulonis, UA. Updated Results from the Phase 1 Expansion Study of Upifitamab Rilsodotin (UpRi; XMT-1536), a NaPi2b-directed Dolaflexin Antibody Drug Conjugate (ADC) in Ovarian Cancer. Society of Gynecologic Oncology 2022 Annual Meeting on Women’s Cancer, Phoenix, Arizona, March 18-21, 2022.

115. Hardesty MM, Krivak T, Wright GS, Hamilton E, Fleming EL, Belotte J, Keeton E, Chen J, Clements A, Gray HJ, Konecny GE, Moore RG, Richardson DL. OVARIO, A Phase 2 Study of Niraparib + Bevacizumab in Advanced Ovarian Cancer Following Front-Line Platinum-Based Chemotherapy with Bevacizumab: Updated Analysis. Society of Gynecologic Oncology 2022 Annual Meeting on Women’s Cancer, Phoenix, Arizona, March 18-21, 2022.

116. Monk BJ; Concin N, Richardson DL, Ray-Coquard IL, Pothuri B, Marth C, Bernardo P, Burger RA, Im E, Aldairy W, Coleman RL, Mirza MR. Optimizing the Dose of Upifitamab Rilsodotin (UpRi; XMT-1536), a NaPi2b-directed Dolaflexin Antibody Drug Conjugate (ADC): Updated Analysis of a Phase 1b Expansion Study in Ovarian Cancer. Society of Gynecologic Oncology 2022 Annual Meeting on Women’s Cancer, Phoenix, Arizona, March 18-21, 2022.

117. Patel MR, Makker, V, Oaknin, A, Pignata S, Backes FJ, González-Martín A, Eskander RN, Pothuri, B, Richardson DL, Alvarez Secord A, Van E, Liu JF, Musa F, Penson RT, Wride K, Lepley D, Dusek R, Cameron T, Hamilton E, Concin N. Efficacy and safety of lucitanib + nivolumab in patients with advanced gynecologic malignancies: phase 2 results from the LIO-1 study (NCT04042116; ENGOT-GYN3/AGO/LIO. American Society of Clinical Oncology Annual Meeting, Chicago, Illinois, June 3-7, 2022.

118. Fu S, Nabell L, Pearson AT, Leidner RS, Adkins D, Posner MR, Nieva JJ, Richardson DL, Pimentel A, Goel S,Wong S, Ho AL, Rosenberg AJ, Taylor MH, Abdul Karim R, Iacobucci C, Qing X, Katchar K, Schlienger K, Pfister DG. Recommended Phase 2 Dose (RP2D) of HB-200 Arenavirus-based Cancer Immunotherapies in Patients with HPV16+ Cancers. American Society of Clinical Oncology Annual Meeting, Chicago, Illinois, June 3-7, 2022.

119. Katz M, Gandhi A, Valente A, Holman L, Richardson D. Implementation of a Standard Same Day Discharge Protocol for Minimally Invasive Hysterectomies in the Division of Gynecologic Oncology: A Quality Improvement Project, Western Association of Gynecologic Oncology Annual Meeting, Coeur d’Alene, Idaho, June 17-19, 2022.

120. Richardson DL, Perez Fidalgo JA, Gonzalez Martin A, Oaknin A, Hamilton E, Hays J, Pothuri B, Papadopoulos K, Taylor S, Huang M, Lee YC, Krivak T, Moreno Garcia V, Calvo E, Randall L, Starks D, Ross M, Duska L, Gao B, Poka R, Putiri E, Barrett J, DeMars L, Concin N. UPLIFT (ENGOT-OV67/GOG-3048) A pivotal cohort of the XMT-1536-1 trial of upifitimab rilsodotin (XMT-1536; UPRI), a NAPI2B-directed antibody drug (ADC) in platinum-resistant ovarian cancer (#426). International Gynecologic Cancer Society Global Meeting, New York City, New York, September 29-October 1, 2022.

121. Richardson DL, Harter P, O’Malley DM, Gonzalez Martin A, Herzog TJ, Rogalski C, Burger RA, Mirza MR. UP-NEXT (GOG-3049/ENGOT-OV71-NSGO-CTU): A study of upifitamab rilsodotin (UPRI), A NAPI2B-directed antibody drug conjugate (ADC) in platinum-sensitive recurrent ovarian cancer (#453). International Gynecologic Cancer Society Global Meeting, New York City, New York, September 29-October 1, 2022.

122. Richardson DL, Barve M, Saltos A, Papadopolous K, Hays J, Tolcher A , Ellard S, Doroshow D, Mitchell P, Zarwan C, Werner TL, Anderson C, Spira A, Mileshkin L, Bradshaw C, DeMars L, Mosher R, Hamilton E. COMPARISON OF NAPI2B EXPRESSION FROM PAIRED TISSUE SAMPLES IN A CLINICAL STUDY OF UPIFITAMAB RILSODOTIN (UPRI; XMT-1536) SUPPORTS A STRATEGY OF TESTING IN ARCHIVE MATERIAL. International Gynecologic Cancer Society Global Meeting, New York City, New York, September 29-October 1, 2022.

123. Holloway RW, Thaker PH, Mendivil AA, Ahmad S, Bell MC, Chambers SK, Chan JK, Coleman RL, Crafton SM, Crane E, Eskander R, Finkelstein K, Graybill1 W, Thomas J. Herzog TJ, John VS, Landrum L, Leiser A, McHale MT, Miller RW, Monk BJ, Moore KN, O’Malley DM, Reid T, Richardson DL, Silasi DA, Sunde JS, Tewari K. Phase 3 study of efficacy & safety of OLVI-VEC and platinum doublet + bevacizumab compared to platinum-doublet + bevacizumab in platinum-resistant/refractory ovarian cancer (ONPRIME; GOG-3067) [NCT05281471]. International Gynecologic Cancer Society Global Meeting, New York City, New York, September 29-October 1, 2022.

124. Hile E, Fox A, Bell J, Xu C, Richardson D, Moore K. Report of worse activity interference from concentration and memory problems partially explains digit symbol substitution declines during neurotoxic chemotherapy in women's cancers: exploratory analysis from an observational pilot. International Society for Geriatric Oncology Annual Conference, Geneva, Switzerland, October 28-30, 2022.

125. Rives TA, Lui J, Chon HS, Avila M, Cosgrove C, Corr BR, Dood RL, Edge SB, Leiser AL, Washington C, Richardson D, Holman L, Craig DW, Moskaluk CA, Phippen N, Landrum L, Churchman M, Miller RW, Dietrich CS, Ueland FR, Wang C, Kolesar JM. Comparison of the clinical and genomic profiles of endometrial cancers in Appalachian and non-Appalachian patients. ORIEN Scientific Retreat

126. Swisher EM, Duska LR, Hamilton E, Oza A, Fleming GF, Yeku OO, Spira A, Richardson DL, Guo R, Walling J, Inokuchi K, Zamarin D. Phase 1b/2a clinical trial of the oral BET inhibitor PLX2853 as monotherapy for ARID1A mutated gynecologic cancers and in combination with carboplatin for platinum resistant ovarian cancer. AACR 2023 Annual Meeting Orlando, Florida, April 14-19, 2023.

127. Call J, Orr D, Anderson I, Richardson DL, Chen Z, Ma S,  Hunder N, Hamilton E.  Phase 1/2 study of PRO1184, a novel folate receptor alpha-directed antibody-drug conjugate, in patients with locally advanced and/or metastatic solid tumors. AACR 2023 Annual Meeting Orlando, Florida, April 14-19, 2023.

128. Richardson DL, Quintanilha JCF, Graf R, Danziger N, Washington C, Dockery LE, Snow T, Afghahi A, Frachioni A, Elvin JA, Moore KN. Effectiveness of PARP inhibitor maintenance therapy (mPARPi) in advanced ovarian cancer (OC) by BRCA1/2 and HRD signature in real-world practice. 2023 American Society of Clinical Oncology Annual Meeting, Chicago, Illinois, June 2-6, 2023.

129. Richardson DL, Harter P, O'Malley DM, Gonzalez Martin A, Herzog TJ, Rogalski C,  Lemming R, Keeton E, Burger RA, Mirza MR. UP-NEXT (GOG-3049/ENGOT-Ov71-NSGO-CTU): A study of upitifamab rilsodotin (UpRi), a NaPi2b-directed antibody drug conjugate (ADC), in platinum-sensitive recurrent ovarian cancer. 2023 American Society of Clinical Oncology Annual Meeting, Chicago, Illinois, June 2-6, 2023.

130. Richardson DL, Barve MA, Hamilton EP, Taylor SK, Anderson CK, Buscema J, Huang M, Arend RC, Hays JL, Thaker PH, Lakhani NJ, Mosher R, Shaw P, Bradshaw C, Lu M. Correlating expression of NaPi2b and FRa in high grade serous ovarian cancer (HGSOC). American Society of Clinical Oncology Annual Meeting, Chicago, Illinois, June 2-6, 2023.

131. Leath III CA, Deng W, Mell LK, Richardson DL, Walker JW, Holman LL, Lea JS, Amarnath SR, Santos-Reyes LJ, Arend RC, Mayadev J, Jegadeesh N, DiSilvestro P,  Chon HS, Ghamande SA, Quick AM, Chino JP, MacKay H, Aghajanian C, Monk BJ. Incorporation of triapine (T) to cisplatin chemoradiation (CRT) for locally advanced cervical and vaginal cancer: Results from NRG-GY006, A Phase III Randomized Trial (NCT02466971). 2023 American Society of Clinical Oncology Annual Meeting, Chicago, Illinois, June 2-6, 2023.

132. Lakhani NJ, Stewart, D, Richardson, DL, Dockery LE, Van Le L, Call J, Rangwala F, Scholl A, Guanfang Wang, Ma B, Metenou S, Gonzalez L, Pandite L, Hamilton E. Phase 1 dose escalation study of SL-172154 (SIRPα-Fc-CD40L) in platinum-resistant ovarian cancer. 2023 American Society of Clinical Oncology Annual Meeting, Chicago, Illinois, June 2-6, 2023.

133. Falchook G, Patnaik A, Sharma MR, Harvey RD, Hamilton E, Wise-Draper TM, Barve M, Patel MR, Dowlati A, Richardson DL, Faltermeier C, Ewesuedo R, Kneissl M, Potocka E. TABLET: Relative bioavailability and bioequivalence study of niraparib tablets and capsules in patients with advanced solid tumors. American College of Clinical Pharmacology Congress, Bellevue, Washington, September 10-12, 2023.

134. Nabell L, Ho AL, Posner MR, Neupane P, Naqash AR, Wong S, Niu J,  Pearson AT, Laux D, Adkins D, Pimentel1 A, Rosenberg AJ, Richardson DL, Wong W, Kaufmann T, Katchar K, Qing X, Iacobucci C, Schlienger K, Pfister DG. HB-200 arenavirus-based immunotherapy plus pembrolizumab as a first-line treatment of patients with recurrent/metastatic HPV16 positive head and neck cancer. European Society of Medical Oncology, Madrid, Spain, October 20-24, 2023.

135. Call J, Anderson I, Winer I, Orr D, Yeku O, Richardson D,  Zhang J, Lee E, Konecny G, Li N, Patel S, Wu L, Wang J, Zhang J, Cheng Y, Wu X, Hunder N, Liu L, Ma S, Song E,  Hamilton E. A Phase 1/2 study of Rinatabart Sesutecan (Rina-S™; PRO1184), a Novel Folate Receptor α-Directed Antibody-Drug Conjugate, in Patients with Locally Advanced and/or Metastatic Solid Tumors. Society for Immunotherapy of Cancer Annual Meeting, San Diego, California, November 1-5, 2023.

136. Ho AL, Pearson AT, Fu S, Posner MR, Adkins D, Nabell L, Niu J, Richardson DL, Leidner R, Chung K, Laux D, Nieva J, Wong S, Rojas K, Rosenberg AJ, Phan M, Kaufmann T, Plescia C, Qing X, Iacobucci C, Tchakov I, Katchar K, Orlinger K, Schlienger K,  Pfister DG. Characterization of Tumor-Specific CD8+ T Cell Responses in Patients with Recurrent/Metastatic HPV16-Positive Head and Neck Cancer Receiving HB-200 Monotherapy as Second or Later-Line Treatment in a Phase 1 Study. Society for Immunotherapy of Cancer Annual Meeting, San Diego, California, November 1-5, 2023.

137.  Duska LR, Richardson DL, Jada SR, Gupta S, Teja TLR, Alvarez Secord A. Phase 2, Single Arm Clinical Trial to Evaluate the Safety and Activity of Oregovomab and Niraparib In Subjects with Platinum Sensitive Recurrent Ovarian Cancer: FLORA-4. International Gynecologic Cancer Society Annual Global Meeting, Seoul, Korea, November 5-7, 2023.

138. Richardson DL, Iyer G, Ding L, Schmid AN, Navarro WH, Kwiatkowski DJ, Ahnert JR. Phase 2, multicenter, open-label basket trial of nab-sirolimus for malignant solid tumors harboring pathogenic inactivating alterations in TSC1 and TSC2 (PRECISION I), Trial in Progress. AACR Endometrial Meeting, Boston, Massachusetts, November 16-18,2023.

139. Khormi A, Cha A, Xu C, Richardson DL, Moore KN, Hile E. Longitudinal Associations Between Appendicular Lean Mass and Strength with Cumulative Taxane-Platinum for Women’s Cancer. American Physical Therapy Association-CSM, Bostin, Massachusetts, February 1-17, 2024.

140. Richardson DL, Falchook G, Harvey RD, Sharma M, Hafez N,  Hamilton E, Patnaik A, Piha-Pau SA, Barve M, Wise-Draper T, Patel MR, Dowlati A, Pascuzzo J,  Tang SC, Faltermeier C, Malinowska IA, Shtessel L, Striha A, Potocka E. TABLET: Food Effect Study Of Niraparib Tablets In Patients With Advanced Solid Tumours. European Society of Gynecologic Oncology 2024 Congress, Barcelona, Spain, March 7-10, 2024.

141. Richardson DL, Iyer G, Ding L, Schmid AN,  Palma NA, Navarro WH, Ahnert JR. nab-Sirolimus for Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 and TSC2 in a Phase 2, Multicenter, Open-label Basket Trial: PRECISION 1. SGO 2024 Annual Meeting on Women’s Cancer, San Diego, California, March 15-18, 2024.

142. Concin N, Hays J, Perez Fidalgo A, Pothuri B, Banerjee S, Ghamande S, Ray-Coquard I, Germanova A, Rimel BJ, Lorusso D, Cloven N, Baurain JF, Randall L, Brasiuniene B, Tseng J, Mazurkiewicz DK, Werner TL, Oaknin A, Ang JE, Leary A, Bishop E, Marth C, Bradshaw C, Burger R, Gonzalez-Martin A, Richardson DL. UPLIFT (ENGOT-ov67/GOG-3048): Results from the Phase 2 trial of Upifitamab rilsodotin (UpRi; XMT-1536), a NaPi2b-Directed Dolaflexin Antibody-Drug Conjugate (ADC) in Platinum-Resistant Ovarian Cancer, SGO 2024 Annual Meeting on Women’s Cancer, San Diego, California, March 15-18, 2024.

143. Dockery L, Richardson DL, Neff R, Green AK, Priebe A, Iyer G, Palma NA, Navarro WH, Moore K. Analysis of inactivating TSC1 and TSC2 alterations in a real-world patient population with advanced gynecological cancers in the Foundation Medicine genomic database, SGO 2024 Annual Meeting on Women’s Cancer, San Diego, California, March 15-18, 2024.

144. Single-Arm Phase II Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy with Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer who are Folate Receptor α positive, SGO 2024 Annual Meeting on Women’s Cancer, San Diego, California, March 15-18, 2024.

145. Duska, L, Angeles Secord A, Richardson DL, Jada S, Gupta S. Phase 2, single arm clinical trial to evaluate the safety and activity of oregovomab and niraparib as a combinatorial immune priming strategy in subjects with platinum sensitive recurrent ovarian cancer: FLORA-4 study. American Society of Clinical Oncology Annual Meeting, Chicago, Illinois, May 30-June 4, 2024.

146. Yonemori K, Banda K, Boni V, Sohn J, Meniawy TM, Lombard JM, Kaufman PA, Richardson DL, Bender L, Matsumoto K, Giridhar KV, Garcia-Saenz JA, Prenen H, Uribe BDS, Dizon DS, Garcia-Corbacho J, Li Y, Nguyen B, Ismail-Khan R, Neven P. Imlunestrant, an oral Selective Estrogen Receptor Degrader (SERD), as Monotherapy and in Combination with Abemaciclib, in Endometrioid Endometrial Cancer: Results from the EMBER Phase 1a/1b Study. American Society of Clinical Oncology Annual Meeting, Chicago, Illinois, May 30-June 4, 2024.

147. Makker V, Richardson DL, Sook Chon H, Miller DS, Mau-Sorenson M, Cibula D, Zapouri F, Perez Fidalgo A, Slomovitz BM, Coleman RJ, Kalyanapu P, Fan R, Gudi G, Vergote I. Phase 3 dose selection for selinexor in TP3wt endometrial cancer based on exposure-response analysis. American Society of Clinical Oncology Annual Meeting, Chicago, Illinois, May 30-June 4, 2024.

148. Ray-Coquard I, Richardson DL, Hasegawa K, Mailley C, Re S, Kundu MG, Lin J, Moore K. REJOICE-Ovarian01: a Phase 2/3 study of raludotatug deruxtecan (R-DXd) in patients with platinum-resistant ovarian cancer. American Society of Clinical Oncology Annual Meeting, Chicago, Illinois, May 30-June 4, 2024.

149. Lee EK, Yeku O,  Winer I, Hamilton E, Richardson DL, Zhang J,  Konecny G, Anderson I,  Wu X, Orr D, Patel SP,  Jewell A, Wang J, Spira A, Melnyk A, Seamon L, Kavalerchik E, Chen Z, Song E, Call J. A Phase 1/2 study of Rinatabart Sesutecan (Rina-S) in Patients with Advanced Ovarian or Endometrial Cancer. European Society of Medical Oncology Barcelona, Spain, 13-17, 2024

150. Schram AM, De Lima Lopes G, El-Khoueiry A, Fontana E, Johnson M, Karasic T,  Kumar S, Lorusso P, Gregorc V, Millward M, Aix SP,  Richardson DL, Roda Perez D, Spira A, Peng Tan DS, Thompson J, Uprety D, Fellous M,  Le Duke K, Qin YG,  Dumbrava EE. PYNNACLE Phase 2 Trial of Rezatapopt (PC14586) in Solid Tumors with a TP53 Y220C Mutation. European Society of Medical Oncology Barcelona, Spain, 13-17, 2024

151. Dowlati A, Richardson DL, LoRusso P, Spria A, Bashir B, Sheng Q, Chen Y, Hirmand M, Mehta M, Patel MR. AVZO-021-1001: A First-in-Human Open-Label, Multicenter Phase 1/2 Dose-Escalation and Expansion Study Evaluating AVZO-021 in Advanced Solid Tumors. European Society of Medical Oncology Barcelona, Spain, 13-17, 2024

152. Moore KN, Woo S, Richardson DL, Benbrook DM. Ongoing phase I trial of an investigational new drug, SHetA2, in Solid Tumors. Korean Society of Medical Oncology, 2024, Seoul, Korea September 26-27, 2024

153. Thaker PH, Richardson DL, Hageman AR, Holloway R, Reed M, Bergman M, Pothuria B, DePasquale S, Scalici JM, Bregar A, Darus CJ, Finkelsterin K, Leath CA, Bell M, Warshal D, Aghajanian R, Indermaur M, Mendivil A, Provencher D, Borys N, Hazard S, Musso L, Lindborg S, Anwer K, Bradley WH. Phase I/II study of Safety and Efficacy of Intraperitoneal IMNN-001 with Neoadjuvant Chemotherapy of Paclitaxel and Carboplatin in Patients Newly Diagnosed with Advanced Epithelial Ovarian Cancer. ASCO-SITC, Houston, Texas, November 8-10, 2024

154. Part C of a Phase 1/2 Study Evaluating Single-Agent Rinatabart Sesutecan (Rina-S) in Patients With Advanced and/or Metastatic Platinum-Resistant Ovarian Cancer (PROC). SGO 2025 Annual Meeting on Women’s Cancer, Seattle, Washington, March 14-17, 2025

155. Richardson DL, . High Concordance Between Immunohistochemistry (IHC) and Next-Generation Sequencing (NGS) for Determining TP53 Mutation Status in Endometrial Cancer (EC): A Post Hoc Analysis of the ENGOT-EN5/GOG-3055/SIENDO Study. SGO 2025 Annual Meeting on Women’s Cancer, Seattle, Washington, March 14-17, 2025

156. Richardson DL. A phase 2 study of niraparib + bevacizumab maintenance following front-line (1L) platinum-based chemotherapy (CT) with bevacizumab (bev) in advanced ovarian cancer (aOC): final analysis from the OVARIO study. Virtual poster. SGO 2025 Annual Meeting on Women’s Cancer, Seattle, Washington, March 14-17, 2025

157. Richardson DL, Duska L, Zhao D, Holman L, Washington C, Dockery L, Walker J, and Moore KN. Phase II trial of niraparib in combination with dostarlimab in patients with recurrent or progressive cervix cancer (STAR). SGO 2025 Annual Meeting on Women’s Cancer, Seattle, Washington, March 14-17, 2025

158. Richardson DL, . Concordance between Foundation Medicine homologous recombination deficiency signature (HRDsig) and Myriad genomic instability score (GIS). SGO 2025 Annual Meeting on Women’s Cancer, Seattle, Washington, March 14-17, 2025

159. Lee E, … Richardson DL. Rinatabart Sesutecan (Rina-S) for Patients With Advanced Ovarian Cancer: Results from Dose Expansion Cohort B1 of a Phase 1/2 Study. SGO 2025 Annual Meeting on Women’s Cancer, Seattle, Washington, March 14-17, 2025
     
      

PUBLICATIONS

1. Richardson DL, Mariani A, Cliby WA. Risk factors for anastomotic leak after recto-sigmoid resection for ovarian cancer.  Gynecol Oncol 2006; 103:667-72.

2. Richardson DL, Seamon LG, Gong MC, Chapman DM, Cohn DE.  Panniculectomy concurrent with anterior pelvic exenteration for recurrent cervical cancer.  Gynecol Oncol 2008; 108:449-51.

3. Seamon LG, Cohn DE, Valmadre S, Richardson DL, Nickerson E, Fowler JF.  Robotic hysterectomy and lymphadenectomy for endometrial cancer: Technical aspects and details for success, The Ohio State University method.  Journal of Robotic Surgery 2008; 2:71-6.

4. Richardson DL, Seamon LG, Cohn DE.  Response to Letter to the Editor regarding:  Panniculectomy concurrent with anterior pelvic exenteration for recurrent cervical cancer.   Gynecol Oncol 2008; 110:269.

5. Richardson DL, Seamon LG, Carlson MJ, O’Malley DM, Fowler JM, Copeland LJ, Cohn DE.  CA125 decline in ovarian cancer patients treated with intravenous versus intraperitoneal platinum-based chemotherapy.  Gynecol Oncol 2008; 111:233-6. PMID: 18768214

6. Seamon LG, Cohn DE, Richardson DL, Valmadre S, Carlson MJ, Phillips GS, Fowler JM.  Robotic hysterectomy and pelvic-aortic lymphadenectomy for endometrial cancer.  Obstet Gynecol 2008; 112:1201-6.

7. Richardson DL, Backes FJ, Seamon LG, Zanagnolo V, O’Malley DM, Cohn DE, Fowler JM, Copeland LJ.  Combination gemcitabine, platinum, and bevacizumab for the treatment of recurrent ovarian cancer.  Gynecol Oncol 2008; 111:461-6. PMID: 18829088

8. Seamon LG, Richardson DL, Pierce M, Griffin S, Cohn DE.  Local correction of extreme stomal prolapse following transverse loop colostomy.  Gynecol Oncol 2008; 111:549-51. PMID: 18304621

9. Resnick KE, Alder H, Hagan JP, Richardson DL, Croce CM, Cohn DE.  The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. Gynecol Oncol 2009; 112:55-9.

10. Bakkum-Gomez JN, Richardson DL, Seamon LG, Aletti GD, Powless CA, Keeney GL, O’Malley DM, Cliby WA.  Influence of intraoperative capsule rupture on outcomes in stage I epithelial ovarian cancer.  Obstet Gynecol 2009; 113:11-17.

11. Seamon LG, Holt CN, Suarez A, Richardson DL, Carlson MJ, O’Malley DM.  Paratubal serous borderline tumors.  Gynecol Oncol 2009; 113:83-5.

12. Seamon LG, Fowler JM, Richardson DL, Carlson MJ, Valmadre S, Phillips GS, Cohn DE.  A detailed analysis of the learning curve: robotic hysterectomy and pelvic-aortic lymphadenectomy for endometrial cancer.  Gynecol Oncol 2009; 114:162-7.

13. Seward S, Richardson DL, Leon M, Cohn DE, Hitchcock C.  Metastatic squamous cell carcinoma of the vulva to the lung confirmed with allelotyping.  Int J Gynecol Pathol 2009; 28:497-501.

14. Richardson DL, Seamon LG, Resnick KE, Martin D, Fowler JM.  Isolated groin recurrence of vulvar cancer salvaged with multimodality therapy.  Gynecol Oncol 2009; 115:306-7.

15. Seamon LG, Carlson MJ, Richardson DL, Cohn DE, Fowler JM, Copeland LJ, O’Malley DM.  Outpatient platinum-taxane intraperitoneal chemotherapy regimen for ovarian cancer.  Int J Gynecol Oncol 2009; 19:1195-8. PMID:19823054

16. Hurt JD, Richardson DL, Seamon LG, Fowler JM, Copeland LJ, Cohn DE, Eisenhauer E, Salani R, O’Malley DM.  Sustained progression-free survival with weekly paclitaxel and bevacizumab in recurrent ovarian cancer.  Gynecol Oncol 2009; 115:396-400. PMID:19804901

17. Seamon LG, Cohn DE, Richardson DL, Hurt JD, Nickerson EC, Fowler JM.  Robotic pelvic and aortic lymphadenectomy for endometrial cancer: The console surgeon's perspectives on surgical technique and directing the assistant.  J Minim Invasive Gynecol 2010;17:180-5.

18. Richardson DL, Backes FJ, Hurt JD, Seamon LG, Copeland LJ, Fowler JM, Cohn DE, O’Malley DM.  Which factors predict bowel complications in patients with recurrent epithelial ovarian cancer being treated with bevacizumab?  Gynecol Oncol 2010;118:47-51. PMID: 20382413

19. Kothari R, Morrison C, Richardson D, Seward S, O’Malley D, Copeland L, Fowler J, Cohn DE.  The prognostic significance of the triple negative phenotype in endometrial cancer.  Gynecol Oncol 2010; 118:172-5.  PMID:20605625

20. Bakkum-Gomez JN, Richardson DL, Seamon LG, Aletti GD, Powless CA, Keeney GL, O’Malley DM, Cliby WA.  Is there a high-risk subgroup of stage I ovarian cancer most likely to benefit from 6 vs. 3 cycles of adjuvant chemotherapy?  Int J Gynecol Oncol 2010;20:1125-31.

21. O’Malley D, Richardson DL, Rheaume S, Salani R; Eisenhauer E, McCann G, Fowler J, Copeland L, Cohn D, Backes F.  Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer.  Gynecol Oncol 2011;121:269-72. PMID: 21315428

22. Boren TP, Carrick K, Kehoe SM, Lea J, Miller DS, Richardson D.  Correlation of cone biopsy with findings at radical hysterectomy and use of adjuvant radiation therapy.  Gynecol Oncol 2012;124:508-11.

23. Seamon LG, Richardson DL, Copeland LJ.  Evolution of the Gynecologic Oncology Group Protocols in the Treatment of Epithelial Ovarian Cancer.  Clin Obstet Gynecol 2012;55:131-55.

24. Chamsy DJ, Purinton SC, Carrick KS, Richardson DL. Malignant Uterine Perivascular Epithelioid Cell Tumor: A Case Report. Clinical Ovarian and Other Gynecologic Cancer. 2012; 5:37-9.

25. Boren T, Lea J, Kehoe S, Miller DS, Richardson D.  Lymph node metastasis in endometrioid adenocarcinomas of the uterine corpus with occult cervical involvement.  Gynecol Oncol 2012; 127:43-6. 

26. Backes FJ, Richardson DL, McCann GA, Smith B, Salani R, Eisenhauer EL, Fowler JM, Copeland LJ, Cohn DE, O’Malley DM.  Should bevacizumab be continued after progression on bevacizumab in recurrent ovarian cancer? Int J Gynecol Cancer 2013;23:833-8. PMID:23640292

27. Lin K, Bryant S, Miller DS, Kehoe SM, Richardson DL. Lea JS. Malignant ovarian germ cell tumor - role of surgical staging and gonadal dysgenesis. Gynecol Oncol 2014; 134:84-9.

28. Manders DM, Paulsen A, Kehoe SM, Richardson DL, Miller DS, Lea JS. Factors associated with clinical trial screening failures in gynecologic oncology. Gynecol Oncol 2014; 134:450-4.

29. Nagel CI, Denson WN, Richardson DL, Kehoe SM, Miller DS, Lea JS. Survival Outcomes of Clinical Trials in Patients With Recurrent Cervical Cancer. Clinical Ovarian and Other Gynecologic Cancer 2014;6: 42-5.

30. Nagel C, Thomas S, Richardson DL, Kehoe S, Miller D, Lea J. Adnexal masses requiring surgical intervention in women with advanced cervical cancer. Gynecol Oncol 2014; 134:552-5.

31. Lancaster JM, Powell CB, Chen L, Richardson, D. Statement on Risk Assessment for Inherited Gynecologic Cancer Predispositions. Gynecol Oncol 2015;136:3-7.

32. Davidson BA, Nagel CI, Richardson DL, Kehoe SM, Miller DS, Lea JS. Outcomes of Treatment of Gestational Trophoblastic Neoplasia in a Primarily Indigent, Urban Population. J Reprod Med 2015; 60:243-8.

33. Lin KY, Miller DS, Bailey AA, Andrews SJ, Kehoe SM, Richardson DL, Lea JS. Ovarian involvement in endometrioid adenocarcinoma of the uterus. Gynecol Oncol 2015;138:532-5.

34. Davidson BA, Nagel CI, Richardson DL. Skin Metastases to Cesarean Scar at Diagnosis of Carcinoma of Cervix in a Postpartum Female. Cervical Cancer 2015;1:102. doi:10.4172/ccoa.1000102

35. Kho K, Lin K, Hechanova M, Richardson DL. Risk of occult uterine sarcoma in women undergoing hysterectomy for benign indications. Obstetrics and Gynecology 2016;127:468-73.

36. Tumati V, Folkert MR, Lawson S, Wise E, Wolcott S, Richardson D,  Carlson M,  Kehoe S, Lea J, Abdulrahman R,  Albuquerque K. Remote location interstitial brachytherapy with patient stabilization and subsequent transport to an outpatient center for treatment is safe and effective for the treatment of gynecologic malignancies. Brachytherapy 2016;15:341-6.

37. Conrad LB, Conrad SA, Miller DS, Richardson DL, Kehoe S, Lea JS. Factors influencing primary treatment of midline vulvar cancers. Gynecol Oncol 2016;142:133-8.

38. Bedell S, Manders D, Kehoe S, Lea J, Miller D, Richardson D, Carlson M. The opinions and practices of providers toward the sexual issues of cervical cancer patients undergoing treatment. Gynecol Oncol 2016;143(1):211-12.

39. Committee on Gynecologic Practice, Society of Gynecologic Oncology. Committee Opinion No. 716: The Role of the Obstetrician-Gynecologist in the Early Detection of Epithelial Ovarian Cancer in Women at Average Risk. Obstet Gynecol. 2017 Sep;130(3):e146-e149

40. Cohn DE, Sill MW, Walker JL, O'Malley D, Nagel CI, Rutledge TL, Bradley W, Richardson DL, Moxley KM, Aghajanian C. Randomized phase IIB evaluation of weekly paclitaxel versus weekly paclitaxel with oncolytic reovirus (Reolysin®) in recurrent ovarian, tubal, or peritoneal cancer: an NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol 2017;146(3):477-83.

41. Richardson DL, Sill MW, Coleman RL, Sood AK, Pearl ML, Kehoe SM, Carney ME, Hanjani P, Van Le L, Zhou XC, Alvarez Secord A, Gray HJ, Landrum LM, Lankes HA, Hu W, Aghajanian C. Paclitaxel With and Without Pazopanib for Persistent or Recurrent Ovarian Cancer: A Randomized Clinical Trial. JAMA Oncol 2018:4;196-202.

42. Manders DB, Kehoe SM, Miller DS, Lea JS, Richardson DL. Third-line salvage chemotherapy for recurrent carcinoma of the cervix is associated with minimal response rate and high toxicity. Am J Clin Oncol 2018;41:797-801.

43. Manders DB, Morón A, McIntire D, Miller DS, Richardson DL, Kehoe SM, Albuquerque KV, Lea JS. Locally advanced cervical cancer - outcomes with variable adherence to treatment. Am J Clin Oncol 2018;41:447-451.

44. Palavalli Parsons LH, Roane B, Manders DB, Richardson DL, Kehoe SM, Carlson M, Miller DS, Lea JS. Hypoalbuminemia is a predictive factor for fistula formation in recurrent cervical cancer, Am J Clin Oncol 2018;41:933-937.

45. Palavalli Parsons LH, Pederson R, Richardson, DL, Kho K. The prevalence of occult endometrial cancer in women undergoing hysterectomy for benign indications. Eur J Obstet Gynecol Reprod Biol 2018;223:108-12.

46. Manders DB, Sims TT, Albuquerque KV, Carlson MJ, Richardson DL, Kehoe SM, Miller DS, Lea JS. Emphasis on systemic therapy in women with pelvic bone metastasis at time of diagnosis of cervical cancer. Am J Clin Oncol 2018;41:1137-1141.

47. Manders DB, Sims TT, Bailey A, Hwang L, Richardson D, Miller D, Kehoe S, Albuquerque K, Lea JS. The significance of para-aortic nodal size and role of adjuvant systemic chemotherapy in cervical cancer- an institutional experience. Am J Clin Oncol 2018;41:1225-1230.

48. Richardson DL, Seward SM, Moore KN. Antibody drug conjugates in the treatment of epithelial ovarian cancer. Hematology/Oncology Clinics of North America 2018:32, 1057-1071.

49. Gillen J, Richardson D, Moore K. Angiopoietin-1 and Angiopoietin-2 Inhibitors: Clinical Development. Curr Oncol Rep 2019;21:22.

50. Chohan L, Richardson D. ACOG Committee Opinion No. 774: Opportunistic Salpingectomy as a Strategy for Epithelial Ovarian Cancer Prevention. Obstet Gynecol 2019;133:e279-e284.

51. Richardson DL. New and Novel Therapies for Gynecologic Cancers.  Semin Oncol Nurs 2019;35:217-219.

52. Washington C, Richardson DL, Moore KN. Olaparib in the treatment of ovarian cancer. Future Oncol 2019;15:3435-3449.

53. Beavis AL, Yen TT, Stone RL, Wethington SL, Carr C, Son J, Chambers L, Michener C, Ricci S, Burkett W, Richardson DL, Staley AS, Ahn S, Gehrig PA, Torres D, Dowdy SC, Sullivan M, Modesitt S, Watson CH, Veade A, Ehrisman J, Havrilesky L, Secord A, Loreen A, Griffin K, Jackson A, Viswanathan A, Jagar L, Fader AN. Adjuvant therapy for early stage, endometrial cancer with lymphovascular space invasion: is there a role for chemotherapy? Gynecol Oncol 2020;156:568-574.

54. Albuquerque K, Tumati V, Lea J, Ahn C, Richardson D, Miller D, Timmerman R. A phase II trial of stereotactic ablative radiation therapy as a boost for locally advanced cervical cancer. Int J Radiat Oncol Biol Phys 2020;106:464-471.

55. Chase D, Monk B, Ramondetta L, Penson R, Landrum L, Leitao M, Oaknin A, Huh W, Robinson K, Guntupalli S, Richardson D, Salani R, Sill M, Wenzel L, Tewari K. Patient-reported outcomes at discontinuation of anti-angiogenesis therapy in the randomized trial of chemotherapy with bevacizumab for advanced cervical cancer: An NRG Oncology Group study. Int J Gynecol Cancer 2020;30:596-601.

56. Tewari KS, Sill MW, Monk BJ, Penson RT, Moore DH, Lankes HA, Ramondetta LM, Landrum LM, Randall LM, Oaknin A, Leitao M, Eisenhauer EL, DiSilvestro P, Van Le L, Pearl ML, Burke JJ, Salani R, Richardson DL, Michael HE, Kindelberger DW, Birrer MJ. Circulating tumor cells in advanced cervical cancer: NRG Oncology - Gynecologic Oncology Group Study 240 (NCT 00803062). Mol Cancer Ther 2020;19:2363-2370. PMID: 32847980

57. Son J, Chambers LM, Carr C, Michener C, Yao M, Beavis A, Yen TT, Stone R, Wethington S, Fader AN, Burkett WC, Richardson DL, Staley AS, Ahn S, Gehrig P, Torres D, Dowdy SC, Sullivan MW, Modesitt S, Watson C, Veade A, Ehrisman J, Havrilesky L, Secord AA, Loreen A, Griffin K, Jackson A, Viswanathan AN, Ricci S. Adjuvant treatment improves overall survival in women with high intermediate risk early stage endometrial cancer with lymphovascular space invasion. Int J Gynecol Cancer 2020;30:1738-47.

58. Gillen JM, Grimes SC, Essel KG, Duininck GE, Zhao D, Thompson JS, Richardson DL. Impact of financial assistance programs on time to completion of therapy in women receiving chemoradiation for cervical cancer. Gynecol Oncol Reports 2020;34:100660.

59. Richardson DL. Should we or should we not: secondary debulking in ovarian cancer. Invited comment Lancet Oncology 2021;22:412-13. PMID: 33705694

60. Jackson CG, Moore KN, Cantrell L, Erickson BK, Duska LR, Richardson DL, Landrum LM, Holman LL, Walker JL, Mannel RS, Moxley KM, Queimado L, Cohoon A, Ding K, Dockery LE. A Phase II Trial of Bevacizumab and Rucaparib in Recurrent Carcinoma of the Cervix or Endometrium. Gynecol Oncol 2022;2022:166:44-49.  PMID: 35491267 DOI: 10.1016/j.ygyno.2022.04.016

61. Hardesty MM, Krivak TC, Wright GS, Hamilton E, Fleming EL, Belotte J, Keeton EK, Wang P, Gupta D, Clements A, Gray HJ, Konecny GE, Moore RG, Richardson DL. OVARIO phase II trial of combination niraparib plus bevacizumab maintenance therapy in advanced ovarian cancer following first-line platinum-based chemotherapy with bevacizumab Gynecol Oncol 2022;166:219-29. PMID: 35690498

62. Zhou X, Richardson DL, Dowlati A, Goel S, Sahebjam S, Strauss J, Chawla S, Wang D, Mould DR, Samnotra V, Faller DV, Venkatakrishnan K, Gupta N.^. Effect of Pevonedistat, an Investigational NEDD8-Activating Enzyme Inhibitor, on the QTc Interval in Patients with Advanced Solid Tumors. Clinical Pharmacology in Drug Development 2023;12:257-66. PMID: 36382849

63. Krause D and Richardson DL. Is there a role for secondary debulking in ovarian cancer? A review of the current literature. Curr Opin Obstet Gynecol 2023;35:1-5. PMID: 36239548

64. Tymon-Rosario J, Gorman M, Richardson DL, Washington C, Santin A. Advances in Antibody-Drug Conjugates for Gynecologic Malignancies. Curr Opin Obstet Gynecol 2023;35:6-14. PMID: 36484278

65. Banerjee S, Drapkin, R, Richardson DL, Birrer M. Targeting Napi2b in ovarian cancer. Cancer Treatment Reviews 2023;112:102489.  PMID: 36446254 DOI: 10.1016/j.ctrv.2022.102489

66. Richardson DL. Ocular toxicity and mitigation strategies for antibody drug conjugates in gynecologic oncology. Gynecologic Oncology Reports 2023;46  PMID: 37033209 DOI: 10.1016/j.gore.2023.101148

67. Richardson DL, Eskander RN, O’Malley DM. Advanced in Ovarian Cancer Care and Unmet Treatment Needs for Patients with Platinum Resistance: A Narrative Review. JAMA Oncol 2023;9:851-9. PMID: 18304621 DOI: 10.1016/j.ygyno.2008.01.029

68. Vergote I, Pérez-Fidalgo JA, Hamilton EP, Valabrega G, Van Gorp T, Sehouli J, Cibula D, Levy T, Welch S, Richardson DL, Guerra EM, Scambia G, Henry S, Wimberger P, Miller D, Klat J, Martínez-Garcia M.D J, Raspagliesi F, Pothuri B, Romero I, Bergamini A, Slomovitz B, Schochter F, Høgdall E, Fariñas-Madrid L, Monk BJ, Michel D, Kauffman MG, Shacham S, Mirza MR, Makker V,on behalf of the ENGOT-EN5/GOG-3055/SIENDO investigators. Oral selinexor as maintenance therapy after first-line chemotherapy for advanced or recurrent endometrial cancer. J Clin Oncol 2023;41:400-10. PMID: 37669480

69. Duska LR, Zamarin D, Hamilton E, Oza A, Fleming G, Spira A, Yeku O, Richardson D, Walling J, Inokuchi K, Matusow B, Bollag G, Swisher E. A Phase 2a Study of PLX2853 in Gynecological Cancers with known ARID1A Mutation and Phase 1b/2a Study of PLX2853/Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer. In Press JCO Precis Oncol 2023;7:e230023 PMID 37797273

70. Holloway RW, Thaker P,  Mendivil AA, Ahmad S, Al-Niaimi AN, Barter J, Beck T, Chambers SK, Coleman RL, Crafton SM, Crane E, Eskander R, Ghamande S, Graybill W, Herzog T, Indermaur M, John VS,  Landrum L, Lim PC, Lucci JA, McHale M, Monk BJ, Moore KN, Morris R, O’Malley DM, Reid TJ, Richardson D, Rose PG, Scalici JM, Silasi D, Tewari K, Wang EW. A phase III, multicenter, randomized study of olvimulogene nanivacirepvec followed by platinum-doublet chemotherapy and bevacizumab compared with platinum-doublet chemotherapy and bevacizumab in women with platinum-resistant/refractory ovarian cancer. Int J Gynecol Cancer 2023;33:1458-63. PMID: 37666539

71. Bashir B, Wang JS, Falchook G, Fontana E, Arkenau HT,  Carter L, Galot R, Basu B, Bessudo A, Greystoke A, Subbiah V, Richardson DL, Orr H, Bennett G, Sharma R, Xu H,  Paganoni P, Xu C,  Campbell C, McKean M. Results from First-in-Human Phase I Dose-Escalation Study of a Novel Bicycle Toxin Conjugate Targeting EphA2 (BT5528) in Patients with Advanced Solid Tumors. J Clin Oncol 2024;42:3443-52. PMID: 39231383 

72. Falchook G, Patnaik A, Richardson DL, Harvey RD, Sharma MR, Hafez N, Hamilton E, Piha-Paul SA, Barve M, Wise-Draper T, Patel MR, Dowlati A, Pascuzzo J, Tang SC, Faltermeier C, Malinowska IA, Shtessel L, Striha A, Potocka E. A Relative Bioavailability, Bioequivalence, and Food Effect Study of Niraparib Tablets in Patients with Advanced Solid Tumors. In Press Clin Therapeutics 2024

73. Richardson DL, Moore KN, Vergote I, Gilbert L, Martin LP, Mantia-Smaldone GM, Castro CM, Provencher D, Matulonis UA, Stec J, Wang Y, Method M, O’Malley, DM.
    Phase 1b Study of Mirvetuximab Soravtansine, a Folate Receptor Alpha (FRα)–Targeting Antibody-Drug Conjugate, in Combination With Carboplatin and Bevacizumab in Patients With Platinum-Sensitive Ovarian Cancer. Gynecol Oncol 2024;185:186-93.

74. Vergote I,  Perez Fidalgo JA, Valabrega G, Monk BJ, Herzog TJ, Cibula D, Colombo N, Bhavana Pothuri B, Sehouli J, Korach J, Barlin JN, Papadimitriou C, Van Gorp T, Richardson DL, McCarthy M, Antill Y, Mirza MR, Li K, Kalyanapu P, Slomovitz B, Coleman RL. ENGOT-EN20/GOG-3083/XPORT-EC-042 A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients with P53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma: Rationale, Methods, and Trial Design. In Press Int J Gynecol Cancer 2024

75. Makker V, Perez-Fidalgo JA, Valabrega G, Hamilton E, Van Gorp T, Sehouli J, Reginacova K, Richardson DL, Perri T, Oza AM, Miller DS, Guerra Alia EM, De Giorgi U, Henry S, Spitz DL, Wimberger P, Bednarikova M, Sook Chon H, Martinez-Garcia J, Pisano C, Vergote I. Long-term follow-up of efficacy and safety of selinexor maintenance treatment in patients with TP53wt advanced or recurrent endometrial cancer: A subgroup analysis of the ENGOT-EN5/GOG-3055/SIENDO study. Gynecol Oncol 2024; 30:4644-53. PMID: 39078736

76. Richardson DL, Quintanilha JCF, Danziger N, Li G, Sokol E, Schrock AB, Ebot E, Bhardwa N, Norris T, Afghahi A,  Frachioni A, Washington C,  Dockery L, Elvin J, Graf  RP, Moore KN. Effectiveness of PARP inhibitor maintenance therapy in ovarian cancer by BRCA1/2 and a scar-based HRD signature in real-world practice. Clin Cancer Res 2024;30: 4644-53. PMID: 39078736

77. Yonemori K, Boni V, Min KG, Meniawy TM, Lombard J, Kaufman PA, Richardson DL, Bender L, Okera M, Matsumoto K, Giridhar KV, García-Sáenz JA, Prenen H, de Speville Uribe BD, Dizon DS, Garcia-Corbacho J, Van Nieuwenhuysen E, Li Y, Estrem ST, Nguyen B, Bacchion F, Ismail-Khan R, Jhaveri K, Banda K. Imlunestrant, an oral selective estrogen receptor degrader, as monotherapy and combined with abemaciclib, in recurrent/advanced ER-positive endometrioid endometrial cancer: Results from the phase 1a/1b EMBER study. Gynecol Oncol. 2024 Oct 22;191:172-181. doi: 10.1016/j.ygyno.2024.10.006. Epub ahead of print. PMID: 39442371.

78. Mahalingam D, Owonikoko TK,  Delpassand E, Mulcahy MF,  Kalyan A, Ulahannan S, Cheung K, Izumi Y, Johansen M, Madden T, Shimoyama S, Subach RA, Suzuki T,  Wages DS, Wheeler C, Richardson DL. A Trial of Radiolabeled Antibody, 90Y-FF-21101, for the Treatment of Advanced Ovarian and Other Cancers, In Press Cancer 2024

79. Taylor SE, Behr S, Cooper KL, Mahdi H, Fabian D, Gallion H, Ueland F, Vargo J, Orr B, Girda E, Courtney-Brooks M, Olawaiye AB, Randall LM, Richardson DL, Sullivan SA, Huang M, Christner SM, Beriwal S, Lin Y, Chauhan A, Chu E, Kohn EC, Kunos C, Ivy SP, Beumer JH. Dose finding, bioavailability, and PK-PD of oral triapine with concurrent chemoradiation for locally advanced cervical cancer and vaginal cancer (ETCTN 9892). Cancer Chemother Pharmacol. 2024 Dec 14;95(1):4. doi: 10.1007/s00280-024-04720-1. PMID: 39673591.

80. Lakhani NJ, Stewart D, Richardson DL, Dockery LE, Van Le L, Call J, Rangwala F, Wang G, Ma B, Metenou S, Pandite L, Huguet J, Offman E, Hamilton E. First-in-Human Phase I Trial of the Bispecific CD47 Inhibitor and CD40 Agonist Fc-Fusion Protein, SL-172154 in Patients With Platinum-Resistant Ovarian Cancer. In Press JITC 2024
     

BOOK CHAPTERS

1. Richardson, DL: Vaginal cancer. In Hoffman BL, Schorge JO, Schaffer, JI, et al (eds): Williams Gynecology, 2^nd ed. New York, McGraw-Hill, 2012.

2. Richardson, DL: Cervical cancer. In Hoffman BL, Schorge JO, Schaffer, JI, et al (eds): Williams Gynecology, 2^nd ed. New York, McGraw-Hill, 2012.

3. Richardson, DL: Vaginal cancer. In Hoffman BL, Schorge JO, Bradshaw KD, et al (eds): Williams Gynecology, 3rd ed. New York, McGraw-Hill Education, 2016.

4. Richardson, DL: Cervical cancer. In Hoffman BL, Schorge JO, Bradshaw KD, et al (eds): Williams Gynecology, 3rd ed. New York, McGraw-Hill Education, 2016.

5. Richardson DL: Vaginal cancer. In Hoffman BL, Schorge JO, Halvorson LM, et al (eds): Williams Gynecology, 4^th ed. New York, McGraw-Hill Education, 2020.

6. Richardson DL: Cervical cancer. In Hoffman BL, Schorge JO, Halvorson LM, et al (eds): Williams Gynecology, 4^th ed. New York, McGraw-Hill Education, 2020.

7. Washington CR, Richardson DL, Agyemang AF, Odunsi KO, Moore KN. Promising agents on the horizon Part 1: Novel agents to target treatment resistance in ovarian cancer. In Samimi G and Annunziata C (eds): Overcoming Ovarian Cancer Chemoresistance. Elsevier, 2020.

BOOKS

1. Werner CL, Moschos E, Griffith WF, Beshay VE, Rahn DD, Richardson DL, Hoffman BL (eds): Williams Gynecology, 2^nd Edition Study Guide, New York, McGraw-Hill, 2012.

2. Werner CL, Richardson DL, Chang S, Griffith WF, Hamid CA, Rahn DD, Moschos E, Hoffman BL:  Williams Gynecology 3^rd Edition Study Guide, New York, McGraw-Hill Education, 2016.

PERSONAL ACCOMPLISHMENTS

Completed Fit to Fight triathlon benefiting ovarian cancer July 13, 2008 Mason, Ohio